aspartic acid has been researched along with Alzheimer Disease in 280 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Galantamine is a cholinesterase inhibitor and allosteric potentiating ligand modulating presynaptic nicotinic acetylcholine receptors that is used in the treatment of Alzheimer disease (AD)." | 9.14 | Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease. ( Bartha, R; Borrie, MJ; Penner, J; Rupsingh, R; Smith, M; Wells, JL, 2010) |
| "The purpose of this study was to measure metabolite level changes in patients with newly diagnosed Alzheimer Disease (AD) following four months of donepezil treatment." | 9.13 | High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer disease. ( Bartha, R; Borrie, MJ; Rupsingh, R; Rylett, J; Smith, M; Wells, JL, 2008) |
| "We aimed to test whether in vivo levels of magnetic resonance spectroscopy (MRS) metabolites myo-inositol (mI), N-acetylaspartate (NAA), and choline are abnormal already during preclinical Alzheimer disease (AD), relating these changes to amyloid or tau pathology, and functional connectivity." | 7.83 | Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease. ( Blennow, K; Hansson, O; Minthon, L; Strandberg, O; Sundgren, PC; Voevodskaya, O; Wahlund, LO; Westman, E; Zetterberg, H, 2016) |
| "Truncations of tau protein at aspartic acid421 (D421) and glutamic acid391 (E391) residues are associated with neurofibrillary tangles (NFTs) in the brains of Alzheimer disease (AD) patients." | 7.74 | Accumulation of aspartic acid421- and glutamic acid391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease. ( Basurto-Islas, G; Binder, LI; García-Sierra, F; Guillozet-Bongaarts, AL; Luna-Muñoz, J; Mena, R, 2008) |
| "The purpose of this study was to determine cerebral myo-inositol (mI) in adults with Down syndrome (DS), and to trace the chronobiology of DS to Alzheimer disease (AD)." | 7.69 | Role of increased cerebral myo-inositol in the dementia of Down syndrome. ( Ross, BD; Shonk, T, 1995) |
| "To compare memantine with the most prescribed cholinesterase inhibitor (donepezil) from a clinical viewpoint when administered in early phases of Alzheimer disease (AD), and to find out whether memantine may produce changes in brain metabolite concentrations in comparison with donepezil." | 5.14 | Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy. ( Errea, JM; Fayed, N; Modrego, PJ; Pina, MA; Rios, C; Sarasa, M, 2010) |
| "Galantamine is a cholinesterase inhibitor and allosteric potentiating ligand modulating presynaptic nicotinic acetylcholine receptors that is used in the treatment of Alzheimer disease (AD)." | 5.14 | Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease. ( Bartha, R; Borrie, MJ; Penner, J; Rupsingh, R; Smith, M; Wells, JL, 2010) |
| "The purpose of this study was to measure metabolite level changes in patients with newly diagnosed Alzheimer Disease (AD) following four months of donepezil treatment." | 5.13 | High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer disease. ( Bartha, R; Borrie, MJ; Rupsingh, R; Rylett, J; Smith, M; Wells, JL, 2008) |
| "We aimed to test whether in vivo levels of magnetic resonance spectroscopy (MRS) metabolites myo-inositol (mI), N-acetylaspartate (NAA), and choline are abnormal already during preclinical Alzheimer disease (AD), relating these changes to amyloid or tau pathology, and functional connectivity." | 3.83 | Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease. ( Blennow, K; Hansson, O; Minthon, L; Strandberg, O; Sundgren, PC; Voevodskaya, O; Wahlund, LO; Westman, E; Zetterberg, H, 2016) |
| " Myo-inositol (mI), whose transporter gene is located on chromosome 21, has been associated with dementia in the non-DS population; however, nobody has contrasted brain mI in DS with (DS+) and without (DS-) dementia to other non-DS groups." | 3.77 | Down syndrome with and without dementia: an in vivo proton Magnetic Resonance Spectroscopy study with implications for Alzheimer's disease. ( Archer, N; Beacher, F; Daly, E; Foy, CML; Lamar, M; Lovestone, S; Morris, RG; Murphy, DGM; Murphy, KC; Poppe, M; Prasher, V; Simmons, A, 2011) |
| "Truncations of tau protein at aspartic acid421 (D421) and glutamic acid391 (E391) residues are associated with neurofibrillary tangles (NFTs) in the brains of Alzheimer disease (AD) patients." | 3.74 | Accumulation of aspartic acid421- and glutamic acid391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease. ( Basurto-Islas, G; Binder, LI; García-Sierra, F; Guillozet-Bongaarts, AL; Luna-Muñoz, J; Mena, R, 2008) |
| "In this proton magnetic resonance spectroscopy ((1)H-MRS) study, the authors correlated cognitive improvement after 3 months of treatment with donepezil with changes of N-acetylaspartate (NAA) level and NAA/Creatine (Cr) ratio in the medial temporal and parietal lobe of 17 patients with Alzheimer disease." | 3.73 | Treatment monitoring and response prediction with proton MR spectroscopy in AD. ( Block, W; Freymann, K; Jessen, F; Maier, W; Schild, HH; Traeber, F, 2006) |
| "(1)H-MRS studies have shown abnormalities in brain levels of myo-inositol (mI) and N-acetyl aspartate (NAA) in AD, but the relation of these abnormalities with dementia severity was not examined." | 3.71 | Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study. ( Alexander, GE; Chang, L; Huang, W; Krasuski, JS; Rapoport, SI; Schapiro, MB; Shetty, HU, 2001) |
| "In this study, cognitively intact chronic hypertensive older patients had a higher white matter myoinositol/creatine ratio compared with healthy older subjects, suggesting that myoinositol may be a sensitive marker of the effects of chronic hypertension on the brain." | 3.71 | Proton magnetic resonance spectroscopy reveals similar white matter biochemical changes in patients with chronic hypertension and early Alzheimer's disease. ( Benedetti, C; Catani, M; Cherubini, A; Howard, R; Mariani, E; Mecocci, P; Metastasio, A; Pelliccioli, GP; Senin, U; Tarducci, R, 2002) |
| "The purpose of this study was to determine cerebral myo-inositol (mI) in adults with Down syndrome (DS), and to trace the chronobiology of DS to Alzheimer disease (AD)." | 3.69 | Role of increased cerebral myo-inositol in the dementia of Down syndrome. ( Ross, BD; Shonk, T, 1995) |
| "To evaluate cerebral biochemical abnormalities in patients with frontotemporal dementia and Alzheimer disease and to determine whether proton (hydrogen-1) magnetic resonance (MR) spectroscopy can help differentiate among these two patient groups and healthy (control) subjects." | 3.69 | Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. ( Chang, L; Ernst, T; Mehringer, CM; Melchor, R, 1997) |
| "Dementia was an independent predictor of metabolite values." | 2.73 | Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey. ( Antúnez, C; Carles, R; Fortuna, L; García Santos, JM; Gavrila, D; Jiménez Veiga, J; Navarro, C; Parrilla, G; Salmerón, D; Tormo, MJ; Torres del Río, S, 2008) |
| "Mean Alzheimer's Disease Assessment Scale cognitive subscale scores were improved after treatment with donepezil, relative to placebo, at weeks 6, 12, 18, and 24." | 2.71 | Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. ( Charles, HC; Doraiswamy, PM; Ieni, JR; Krishnan, KR; Mintzer, J; Perdomo, C; Rogers, S; Weisler, R; Yu, X, 2003) |
| "Biochemical abnormalities in Alzheimer's Disease (AD), vascular dementia (VaD) and other primary degenerative dementias have been investigated using MRS." | 2.42 | 1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia. ( Jones, RS; Waldman, AD, 2004) |
| "myo-Inositol was raised by about 15%, again uniformly throughout the brain, but there was no evidence for changed levels of choline." | 2.41 | A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. ( Firbank, MJ; Harrison, RM; O'Brien, JT, 2002) |
| "Familial Alzheimer's disease (FAD) is associated with APP mutations that disrupt the cleavage reaction and increase the production of neurotoxic Aβs, i." | 1.91 | Specific Mutations near the Amyloid Precursor Protein Cleavage Site Increase γ-Secretase Sensitivity and Modulate Amyloid-β Production. ( Futai, E; Hidaka, M; Ogawa, T; Suzuki, R; Takahashi, H; Yoshida, C, 2023) |
| "Furthermore, Aβ42, implicated in Alzheimer's disease, undergoes β-sheet to α-helix transition in presence of PIMT." | 1.56 | The role of isoaspartate in fibrillation and its prevention by Protein-L-isoaspartyl methyltransferase. ( Chakrabarti, P; Chatterjee, BK; Chatterjee, T; Das, G; Dhar, J; Ghosh, S, 2020) |
| "Although the underlying cause of Alzheimer's disease (AD) is not known, the extracellular deposition of β-amyloid (Aβ) is considered as a hallmark of AD brains." | 1.56 | Complete identification of all 20 relevant epimeric peptides in β-amyloid: a new HPLC-MS based analytical strategy for Alzheimer's research. ( Armstrong, DW; Du, S; Readel, ER; Wey, M, 2020) |
| "In the 3xTgAd mouse model of Alzheimer's disease (AD), aging mice also demonstrate low brain glucose metabolism." | 1.56 | A Dietary Ketone Ester Normalizes Abnormal Behavior in a Mouse Model of Alzheimer's Disease. ( Kashiwaya, Y; King, MT; Pawlosky, RJ; Veech, RL, 2020) |
| "The diagnosis of Alzheimer's disease (AD) relies on the presence of amyloidosis and tauopathy, as reflected in cerebrospinal fluid (CSF), independently from the clinical stage." | 1.56 | Cerebrospinal fluid and serum d-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer's disease. ( Calabresi, P; Casamassa, A; Errico, F; Eusebi, P; Gaetani, L; Homma, H; Katane, M; Mancini, A; Miroballo, M; Nisticò, R; Nuzzo, T; Parnetti, L; Usiello, A, 2020) |
| "Neurodegeneration in Alzheimer's disease (AD) is closely associated with the accumulation of pathologic tau aggregates in the form of neurofibrillary tangles." | 1.56 | Autosomal dominant VCP hypomorph mutation impairs disaggregation of PHF-tau. ( Aguirre, GK; Changolkar, L; Darwich, NF; Gibbons, GS; Grossman, M; He, Z; Irwin, DJ; Kim, B; Lee, EB; Luk, KC; Massimo, L; McMillan, CT; Nasrallah, IM; Nguyen, AT; O'Rourke, CM; Papageorgiou, SG; Papatriantafyllou, JD; Phan, JM; Porta, S; Suh, E; Toro, C; Van Deerlin, VM, 2020) |
| "Cholinergic dysfunction in Alzheimer's disease (AD) can be mediated by the neuronal α7 nicotinic acetylcholine receptor (α7nAChR)." | 1.51 | Isomerization of Asp7 in Beta-Amyloid Enhances Inhibition of the α7 Nicotinic Receptor and Promotes Neurotoxicity. ( Adzhubei, AA; Anashkina, AA; Barykin, EP; Garifulina, AI; Hollmann, M; Kasheverov, IE; Kozin, SA; Kruykova, EV; Makarov, AA; Mitkevich, VA; Shelukhina, IV; Spirova, EN; Tsetlin, VI, 2019) |
| "Tau pathology in Alzheimer's disease (AD) includes hyperphosphorylation and truncation of tau." | 1.48 | Pseudo-phosphorylation at AT8 epitopes regulates the tau truncation at aspartate 421. ( Cao, L; Liang, Y; Liu, Y; Wan, W; Xu, Y; Zhu, C, 2018) |
| "In the case of Alzheimer's disease (AD), amyloid β (Aβ)-mediated disruption of synaptic plasticity and memory can be alleviated by interventions that directly remove glutamate or block certain glutamate receptors." | 1.46 | Peripheral Interventions Enhancing Brain Glutamate Homeostasis Relieve Amyloid β- and TNFα- Mediated Synaptic Plasticity Disruption in the Rat Hippocampus. ( Mably, AJ; Rowan, MJ; Walsh, DM; Zhang, D, 2017) |
| "Amnestic mild cognitive impairment (aMCI) is often the prodromal stage to AD." | 1.43 | (1)H-MRS asymmetry changes in the anterior and posterior cingulate gyrus in patients with mild cognitive impairment and mild Alzheimer's disease. ( Chen, W; Chen, X; Guo, Z; Hou, H; Liu, X; Shen, Y; Wei, F, 2016) |
| "Amnestic mild cognitive impairment (aMCI) has been considered to be a transitional state between healthy aging and very mild Alzheimer's disease (AD)." | 1.42 | [Prediction of conversion from amnestic mild cognitive impairment to Alzheimer's disease using proton magnetic resonance spectroscopy]. ( Akiguchi, I; Shiino, A; Watanabe, T, 2015) |
| "We validated the utility of SPM8 plus DARTEL (VSRAD) combined with magnetic resonance spectroscopy (1H MRS) as an adjunct screening technique for dementia due to Alzheimer's disease (AD)." | 1.40 | Utility of SPM8 plus DARTEL (VSRAD) combined with magnetic resonance spectroscopy as adjunct techniques for screening and predicting dementia due to Alzheimer's disease in clinical practice. ( Arai, H; Fujii, C; Hata, S; Higuchi, S; Igarashi, K; Ishii, R; Iwai, N; Moriya, M; Ohrui, T; Suzuki, T; Tokuda, T; Uemura, K; Waragai, M; Yoshida, M, 2014) |
| "Alzheimer's disease is an age-related neurodegenerative disease characterized by deterioration of cognition and loss of memory." | 1.40 | Reversal of metabolic deficits by lipoic acid in a triple transgenic mouse model of Alzheimer's disease: a 13C NMR study. ( Cadenas, E; Díaz Brinton, R; Kanamori, K; Patil, I; Ross, BD; Sancheti, H, 2014) |
| "Myo-inositol (mIns) is a marker of glial cells proliferation and has been shown to increase in early Alzheimer's disease (AD) pathology." | 1.39 | MICEST: a potential tool for non-invasive detection of molecular changes in Alzheimer's disease. ( Cai, K; Crescenzi, R; Hariharan, H; Haris, M; Kogan, F; Nath, K; Reddy, R; Singh, A, 2013) |
| "Amyloid peptides (Aβ) deposited in Alzheimer's disease may carry an N-terminal isoAsp-modification." | 1.39 | A quantitative analysis of spontaneous isoaspartate formation from N-terminal asparaginyl and aspartyl residues. ( Cynis, H; Güttler, BH; Ludwig, HH; Porzel, A; Schilling, S; Seifert, F, 2013) |
| "Agitation and depression are among the commonest behavioural and psychological symptoms exhibited by Alzheimer's disease patients." | 1.39 | Differences in brain metabolism associated with agitation and depression in Alzheimer's disease. ( Fuh, JL; Hung, CW; Lirng, JF; Tsai, CF; Wang, SJ, 2013) |
| "The diagnosis of mild or questionable Alzheimer's disease (AD) depends on clinical criteria that often leave a margin for doubt." | 1.37 | Contribution of 1H spectroscopy to a brief cognitive-functional test battery for the diagnosis of mild Alzheimer's disease. ( Andreiuolo, PA; Bottino, CM; de Oliveira-Souza, R; Moll, J; Silveira de Souza, A; Tovar-Moll, F, 2011) |
| "Amnestic mild cognitive impairment (MCI) is highly predictive of Alzheimer's disease but the pace of deterioration varies across patients." | 1.37 | Longitudinal magnetic resonance spectroscopy as marker of cognitive deterioration in mild cognitive impairment. ( Fayed, N; Modrego, PJ, 2011) |
| "The deficits of Alzheimer's disease (AD) are believed to result, at least in part, from neurotoxicity of beta-amyloid (Abeta), a set of 38-43 amino acid fragments derived from the beta-amyloid precursor protein (APP)." | 1.35 | Long-term prevention of Alzheimer's disease-like behavioral deficits in PDAPP mice carrying a mutation in Asp664. ( Ataie, M; Banwait, S; Bredesen, DE; Galvan, V; Gorostiza, OF; Huang, W; Tang, H; Zhang, J, 2008) |
| "The cognitive decline in Alzheimer's disease (AD) patients has been reported to involve alterations in the medial temporal lobe and the posterior cingulate gyrus." | 1.34 | A decrease in N-acetylaspartate and an increase in myoinositol in the anterior cingulate gyrus are associated with behavioral and psychological symptoms in Alzheimer's disease. ( Horiguchi, J; Inagaki, T; Inami, Y; Kawamukai, T; Miyaoka, T; Okazaki, S; Shinno, H; Utani, E, 2007) |
| "Given the available therapies for Alzheimer's disease, early diagnosis is of paramount importance." | 1.33 | Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. ( Fayed, N; Modrego, PJ; Pina, MA, 2005) |
| "Brain damage in Alzheimer's disease (AD) and mild cognitive impairment (MCI) is widespread with involvement of large portions of the neocortex and the subcortical white matter." | 1.33 | A whole brain MR spectroscopy study from patients with Alzheimer's disease and mild cognitive impairment. ( Benedetti, B; Bozzali, M; Comi, G; Falini, A; Filippi, M; Franceschi, M; Gambini, A; Magnani, G; Mossini, R; Pero, G; Scotti, G, 2005) |
| "Disease-specific metabolic changes in Alzheimer's disease and frontotemporal dementia/Pick complex were examined by proton magnetic resonance spectroscopy at 3." | 1.33 | Magnetic resonance spectroscopic study of Alzheimer's disease and frontotemporal dementia/Pick complex. ( Abe, K; Hattori, N; Mihara, M; Sakoda, S; Sawada, T, 2006) |
| "The tangles of Alzheimer's disease (AD) are comprised of the tau protein displaying numerous alterations, including phosphorylation at serine 422 (S422) and truncation at aspartic acid 421 (D421)." | 1.33 | Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo. ( Berry, RW; Binder, LI; Cahill, ME; Cryns, VL; Guillozet-Bongaarts, AL; Reynolds, MR, 2006) |
| "The deficits characteristic of Alzheimer's disease (AD) are believed to result, at least in part, from the neurotoxic effects of beta-amyloid peptides, a set of 39-43 amino acid fragments derived proteolytically from beta-amyloid precursor protein (APP)." | 1.33 | Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. ( Ataie, M; Banwait, S; Bredesen, DE; Carlson, E; Chevallier, N; Galvan, V; Gorostiza, OF; Greenberg, DA; Jin, K; Logvinova, AV; Sagi, SA; Sitaraman, S, 2006) |
| "Choline (Cho)/Cr was higher than normal in patients with AD, FTLD, and DLB." | 1.32 | 1H MR spectroscopy in common dementias. ( Boeve, BF; Edland, SD; Ferman, TJ; Ivnik, RJ; Jack, CR; Kantarci, K; Knopman, DS; O'Brien, PC; Petersen, RC; Smith, GE; Tang-Wai, DF; Tangalos, EG; Weigand, SD, 2004) |
| "The principal pathological features of Alzheimer's disease (AD) are extracellular amyloid plaques and intracellular neurofibrillary tangles, the latter composed of the microtubule-binding protein tau assembled into paired helical and straight filaments." | 1.32 | Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. ( Abraha, A; Berry, RW; Binder, LI; Chen, F; Cryns, VL; Fu, Y; Gamblin, TC; Garcia-Sierra, F; Guillozet, AL; Lagalwar, S; LaPointe, N; Lu, M; Miller, R; Zambrano, A, 2003) |
| "In patients with Alzheimer's disease, but not in health controls, longitudinal magnetic resonance spectroscopy shows a striking decline in the neuronal marker, N-acetyl aspartate, despite little decline in underlying grey-matter volume." | 1.31 | Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. ( Adalsteinsson, E; Kleinhans, N; Pfefferbaum, A; Spielman, DM; Sullivan, EV, 2000) |
| " In consequence of these acute processes delayed cell death in the MBN and persistent loss of cholinergic fibre projections to the neocortex appear as early as 3 days following the Abeta-induced toxic insult." | 1.31 | beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. ( Abrahám, I; Harkany, T; Kónya, C; Korf, J; Laskay, G; Luiten, PG; Nyakas, C; Penke, B; Sasvári, M; Sebens, JB; Soós, K; Timmerman, W; Tóth, B; Zarándi, M, 2000) |
| "To investigate metabolic changes in Alzheimer's disease (AD), we performed proton MR spectroscopy at 3T Spectra were acquired from the gray matter of the posterior cingulate gyrus and the precuneus, and from the parietooccipital white matter in nine AD patients and 12 controls." | 1.31 | Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease. ( Abe, K; Hattori, N; Sakoda, S; Sawada, T, 2002) |
| "The most common cause of familial Alzheimer's disease is mutation of the genes encoding presenilins 1 and 2, which alters gamma-secretase activity to increase the production of the highly amyloidogenic Abeta42 isoform." | 1.30 | Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. ( Diehl, TS; Kimberly, WT; Ostaszewski, BL; Selkoe, DJ; Wolfe, MS; Xia, W, 1999) |
| "Five elderly normal and five Parkinson's disease (PD) cases were used as controls." | 1.28 | Distribution of neurofibrillary tangle formation and [3H]-D-aspartate receptor binding in the thalamus in the normal elderly brain, in Alzheimer's disease and in Parkinson's disease. ( Bonham, JR; Candy, JM; Marshall, E; Perry, EK; Perry, RH; Xuereb, JH, 1990) |
| "These observations suggest that in Alzheimer's disease there are no major changes in the extracellular concentrations of these putative amino acid transmitters." | 1.27 | Amino acid release from biopsy samples of temporal neocortex from patients with Alzheimer's disease. ( Bowen, DM; Davison, AN; Neary, D; Sims, NR; Smith, CC, 1983) |
| "Both activities were reduced in Alzheimer's disease at all, although generally most extensively in the outer and middle layers of the grey matter whereas activities were near normal in the white matter." | 1.27 | Intralaminar neurochemical distributions in human midtemporal cortex: comparison between Alzheimer's disease and the normal. ( Atack, JR; Blessed, G; Dodd, PR; Edwardson, JA; Fairbairn, AF; Hardy, JA; Perry, EK; Perry, RH; Tomlinson, BE, 1984) |
| "Alzheimer's disease was associated with a reduction in [3H]D-aspartate binding density in temporal cortex and caudate nucleus." | 1.27 | Regional changes in [3H]D-aspartate and [3H]TCP binding sites in Alzheimer's disease brains. ( Cross, AJ; Deakin, JF; Mann, DM; Royston, MC; Simpson, MD; Slater, P, 1988) |
| "Neuritic plaque core amyloid protein in Alzheimer's disease brain tissue was investigated for the extent of amino acid racemization." | 1.27 | Neuritic plaque amyloid in Alzheimer's disease is highly racemized. ( Austin, GE; Mirra, SS; Shapira, R, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (8.21) | 18.7374 |
| 1990's | 59 (21.07) | 18.2507 |
| 2000's | 93 (33.21) | 29.6817 |
| 2010's | 83 (29.64) | 24.3611 |
| 2020's | 22 (7.86) | 2.80 |
| Authors | Studies |
|---|---|
| Hone-Blanchet, A | 1 |
| Bohsali, A | 1 |
| Krishnamurthy, LC | 1 |
| Shahid, S | 1 |
| Lin, Q | 1 |
| Zhao, L | 1 |
| Loring, D | 1 |
| Goldstein, F | 1 |
| John, SE | 1 |
| Fleischer, CC | 1 |
| Levey, A | 1 |
| Lah, J | 1 |
| Qiu, D | 1 |
| Crosson, B | 1 |
| Shad, KF | 1 |
| Soubra, W | 1 |
| Cordato, DJ | 1 |
| Specht, H | 1 |
| Slavov, N | 1 |
| Wang, X | 4 |
| Gao, H | 1 |
| Zhang, X | 1 |
| Qian, S | 1 |
| Wang, C | 1 |
| Deng, L | 1 |
| Zhong, M | 1 |
| Qing, G | 1 |
| Gozdas, E | 1 |
| Hinkley, L | 1 |
| Fingerhut, H | 1 |
| Dacorro, L | 1 |
| Gu, M | 1 |
| Sacchet, MD | 1 |
| Hurd, R | 1 |
| Hosseini, SMH | 1 |
| Suzuki, R | 1 |
| Takahashi, H | 1 |
| Yoshida, C | 1 |
| Hidaka, M | 1 |
| Ogawa, T | 1 |
| Futai, E | 1 |
| Liu, M | 1 |
| Li, M | 1 |
| He, J | 2 |
| He, Y | 1 |
| Yang, J | 1 |
| Sun, Z | 1 |
| Readel, ER | 2 |
| Dhaubhadel, U | 1 |
| Patel, A | 1 |
| Armstrong, DW | 2 |
| Hao, FX | 1 |
| Zeng, MN | 1 |
| Cao, B | 1 |
| Liang, XW | 1 |
| Jiao, XM | 1 |
| Feng, WS | 1 |
| Zheng, XK | 1 |
| Chatterjee, T | 1 |
| Das, G | 1 |
| Chatterjee, BK | 1 |
| Dhar, J | 1 |
| Ghosh, S | 1 |
| Chakrabarti, P | 1 |
| Paredes-Rosan, CA | 1 |
| Valencia, DE | 1 |
| Barazorda-Ccahuana, HL | 1 |
| Aguilar-Pineda, JA | 1 |
| Gómez, B | 1 |
| Du, S | 1 |
| Wey, M | 1 |
| Wong, D | 1 |
| Atiya, S | 1 |
| Fogarty, J | 1 |
| Montero-Odasso, M | 1 |
| Pasternak, SH | 1 |
| Brymer, C | 1 |
| Borrie, MJ | 4 |
| Bartha, R | 4 |
| Wu, J | 1 |
| Bie, B | 1 |
| Foss, JF | 1 |
| Naguib, M | 1 |
| Padala, PR | 1 |
| Padala, KP | 1 |
| Samant, RS | 1 |
| James, GA | 1 |
| Pawlosky, RJ | 1 |
| Kashiwaya, Y | 1 |
| King, MT | 1 |
| Veech, RL | 1 |
| Gupta, R | 1 |
| Ambasta, RK | 1 |
| Kumar, P | 1 |
| Nuzzo, T | 1 |
| Miroballo, M | 1 |
| Casamassa, A | 1 |
| Mancini, A | 1 |
| Gaetani, L | 1 |
| Nisticò, R | 1 |
| Eusebi, P | 1 |
| Katane, M | 1 |
| Homma, H | 1 |
| Calabresi, P | 1 |
| Errico, F | 1 |
| Parnetti, L | 2 |
| Usiello, A | 1 |
| Darwich, NF | 1 |
| Phan, JM | 1 |
| Kim, B | 1 |
| Suh, E | 1 |
| Papatriantafyllou, JD | 1 |
| Changolkar, L | 1 |
| Nguyen, AT | 1 |
| O'Rourke, CM | 1 |
| He, Z | 1 |
| Porta, S | 1 |
| Gibbons, GS | 1 |
| Luk, KC | 1 |
| Papageorgiou, SG | 1 |
| Grossman, M | 1 |
| Massimo, L | 1 |
| Irwin, DJ | 1 |
| McMillan, CT | 1 |
| Nasrallah, IM | 1 |
| Toro, C | 1 |
| Aguirre, GK | 1 |
| Van Deerlin, VM | 1 |
| Lee, EB | 1 |
| Altiné-Samey, R | 1 |
| Antier, D | 1 |
| Mavel, S | 1 |
| Dufour-Rainfray, D | 1 |
| Balageas, AC | 1 |
| Beaufils, E | 1 |
| Emond, P | 1 |
| Foucault-Fruchard, L | 1 |
| Chalon, S | 1 |
| Piubelli, L | 2 |
| Pollegioni, L | 2 |
| Rabattoni, V | 2 |
| Mauri, M | 1 |
| Princiotta Cariddi, L | 1 |
| Versino, M | 1 |
| Sacchi, S | 1 |
| Murtas, G | 1 |
| Müller, L | 1 |
| Power Guerra, N | 1 |
| Stenzel, J | 1 |
| Rühlmann, C | 2 |
| Lindner, T | 2 |
| Krause, BJ | 2 |
| Vollmar, B | 2 |
| Teipel, S | 1 |
| Kuhla, A | 2 |
| Alon, A | 1 |
| Schmidt, HR | 1 |
| Wood, MD | 1 |
| Sahn, JJ | 1 |
| Martin, SF | 1 |
| Kruse, AC | 1 |
| Polei, S | 1 |
| Hadlich, S | 1 |
| Teipel, SJ | 1 |
| Dhanabalan, AK | 1 |
| Kesherwani, M | 1 |
| Velmurugan, D | 1 |
| Gunasekaran, K | 1 |
| Zhang, W | 3 |
| Gu, GJ | 1 |
| Zhang, Q | 1 |
| Liu, JH | 1 |
| Zhang, B | 2 |
| Guo, Y | 1 |
| Wang, MY | 1 |
| Gong, QY | 1 |
| Xu, JR | 1 |
| Waragai, M | 2 |
| Moriya, M | 2 |
| Nojo, T | 1 |
| Yeh, YC | 2 |
| Li, CW | 2 |
| Kuo, YT | 2 |
| Huang, MF | 2 |
| Liu, TL | 2 |
| Jaw, TS | 1 |
| Yang, YH | 1 |
| Kuo, KC | 1 |
| Chen, CS | 2 |
| Robertson, DS | 1 |
| Ha, S | 1 |
| Kim, I | 1 |
| Takata, T | 1 |
| Kinouchi, T | 1 |
| Isoyama, M | 1 |
| Suzuki, M | 1 |
| Fujii, N | 1 |
| Zatsepina, OG | 1 |
| Kechko, OI | 1 |
| Mitkevich, VA | 2 |
| Kozin, SA | 4 |
| Yurinskaya, MM | 1 |
| Vinokurov, MG | 1 |
| Serebryakova, MV | 1 |
| Rezvykh, AP | 1 |
| Evgen'ev, MB | 1 |
| Makarov, AA | 4 |
| Cao, L | 1 |
| Liang, Y | 1 |
| Liu, Y | 2 |
| Xu, Y | 1 |
| Wan, W | 1 |
| Zhu, C | 1 |
| Kulpanovich, A | 1 |
| Tal, A | 1 |
| Weng, YC | 1 |
| Hsiao, IT | 1 |
| Huang, CY | 1 |
| Huang, KL | 1 |
| Liu, CH | 1 |
| Chang, TY | 1 |
| Yen, TC | 1 |
| Lin, KJ | 1 |
| Huang, CC | 1 |
| Barykin, EP | 1 |
| Garifulina, AI | 1 |
| Kruykova, EV | 1 |
| Spirova, EN | 1 |
| Anashkina, AA | 1 |
| Adzhubei, AA | 1 |
| Shelukhina, IV | 1 |
| Kasheverov, IE | 1 |
| Hollmann, M | 1 |
| Tsetlin, VI | 1 |
| Warmack, RA | 1 |
| Boyer, DR | 1 |
| Zee, CT | 1 |
| Richards, LS | 1 |
| Sawaya, MR | 1 |
| Cascio, D | 1 |
| Gonen, T | 1 |
| Eisenberg, DS | 1 |
| Clarke, SG | 1 |
| Gasparovic, C | 1 |
| Prestopnik, J | 1 |
| Thompson, J | 1 |
| Taheri, S | 1 |
| Huisa, B | 1 |
| Schrader, R | 1 |
| Adair, JC | 1 |
| Rosenberg, GA | 2 |
| Kantarci, K | 7 |
| Bittner, DM | 1 |
| Heinze, HJ | 1 |
| Kaufmann, J | 1 |
| Menezes, TL | 1 |
| Andrade-Valença, LP | 1 |
| Valença, MM | 1 |
| Xu, L | 1 |
| Viet, MH | 1 |
| Nguyen, PH | 1 |
| Ngo, ST | 1 |
| Li, MS | 1 |
| Derreumaux, P | 1 |
| Tsai, CF | 1 |
| Hung, CW | 1 |
| Lirng, JF | 1 |
| Wang, SJ | 1 |
| Fuh, JL | 1 |
| Lalande, J | 1 |
| Halley, H | 1 |
| Balayssac, S | 1 |
| Gilard, V | 1 |
| Déjean, S | 1 |
| Martino, R | 1 |
| Francés, B | 1 |
| Lassalle, JM | 1 |
| Malet-Martino, M | 1 |
| Sancheti, H | 1 |
| Kanamori, K | 1 |
| Patil, I | 1 |
| Díaz Brinton, R | 1 |
| Ross, BD | 4 |
| Cadenas, E | 1 |
| Jarero-Basulto, JJ | 2 |
| Luna-Muñoz, J | 2 |
| Mena, R | 2 |
| Kristofikova, Z | 2 |
| Ripova, D | 2 |
| Perry, G | 1 |
| Binder, LI | 6 |
| Garcia-Sierra, F | 5 |
| Yen, CF | 1 |
| Chen, CH | 1 |
| Lee, CC | 1 |
| Liu, GC | 1 |
| Marjańska, M | 1 |
| Weigand, SD | 3 |
| Preboske, G | 1 |
| Wengenack, TM | 1 |
| Chamberlain, R | 1 |
| Curran, GL | 1 |
| Poduslo, JF | 1 |
| Garwood, M | 1 |
| Kobayashi, D | 1 |
| Lin, JC | 1 |
| Jack, CR | 7 |
| Sugiki, T | 1 |
| Utsunomiya-Tate, N | 1 |
| Graff-Radford, J | 1 |
| Boeve, BF | 6 |
| Murray, ME | 2 |
| Ferman, TJ | 2 |
| Tosakulwong, N | 1 |
| Lesnick, TG | 2 |
| Maroney-Smith, M | 1 |
| Senjem, ML | 1 |
| Gunter, J | 2 |
| Smith, GE | 5 |
| Knopman, DS | 5 |
| Dickson, DW | 2 |
| Petersen, RC | 6 |
| Zhong, X | 1 |
| Shi, H | 1 |
| Shen, Z | 1 |
| Hou, L | 1 |
| Luo, X | 1 |
| Chen, X | 3 |
| Liu, S | 1 |
| Zhang, Y | 1 |
| Zheng, D | 1 |
| Tan, Y | 1 |
| Huang, G | 1 |
| Fang, Y | 2 |
| Zhang, H | 1 |
| Mu, N | 1 |
| Chen, J | 1 |
| Wu, R | 1 |
| Ning, Y | 1 |
| Hata, S | 1 |
| Suzuki, T | 1 |
| Ishii, R | 1 |
| Fujii, C | 1 |
| Tokuda, T | 1 |
| Arai, H | 2 |
| Ohrui, T | 1 |
| Higuchi, S | 1 |
| Yoshida, M | 1 |
| Igarashi, K | 1 |
| Iwai, N | 1 |
| Uemura, K | 1 |
| Kumar, S | 1 |
| Mato Abad, V | 1 |
| Quirós, A | 1 |
| García-Álvarez, R | 1 |
| Loureiro, JP | 1 |
| Alvarez-Linera, J | 1 |
| Frank, A | 1 |
| Hernández-Tamames, JA | 1 |
| Shinno, H | 2 |
| Inagaki, T | 2 |
| Miyaoka, T | 2 |
| Okazaki, S | 2 |
| Kawamukai, T | 2 |
| Utani, E | 2 |
| Inami, Y | 2 |
| Horiguchi, J | 2 |
| Suriyajakryuththana, W | 1 |
| Tuntiyatorn, L | 1 |
| Teepprasarn, N | 1 |
| Sukying, C | 1 |
| Glodzik, L | 1 |
| Sollberger, M | 1 |
| Gass, A | 1 |
| Gokhale, A | 1 |
| Rusinek, H | 1 |
| Babb, JS | 1 |
| Hirsch, JG | 1 |
| Amann, M | 1 |
| Monsch, AU | 1 |
| Gonen, O | 2 |
| Zou, JX | 1 |
| Wang, MJ | 1 |
| Lei, XJ | 1 |
| Chen, XG | 1 |
| Penner, J | 2 |
| Wells, JL | 3 |
| Woolmore-Goodwin, SM | 1 |
| Przybelski, SA | 1 |
| Liesinger, AM | 1 |
| Spychalla, A | 1 |
| Gunter, JL | 1 |
| Parisi, JE | 1 |
| Doert, A | 1 |
| Pilatus, U | 2 |
| Zanella, F | 1 |
| Müller, WE | 1 |
| Eckert, GP | 1 |
| Watanabe, T | 3 |
| Shiino, A | 4 |
| Akiguchi, I | 4 |
| Calderón-Garcidueñas, L | 1 |
| Mora-Tiscareño, A | 1 |
| Melo-Sánchez, G | 1 |
| Rodríguez-Díaz, J | 1 |
| Torres-Jardón, R | 1 |
| Styner, M | 1 |
| Mukherjee, PS | 1 |
| Lin, W | 1 |
| Jewells, V | 1 |
| Wang, H | 1 |
| Tan, L | 1 |
| Wang, HF | 1 |
| Yin, RH | 1 |
| Wang, WY | 1 |
| Chang, XL | 1 |
| Jiang, T | 1 |
| Yu, JT | 1 |
| Guo, Z | 2 |
| Zhang, J | 4 |
| Liu, X | 2 |
| Hou, H | 2 |
| Cao, Y | 1 |
| Wei, F | 2 |
| Li, J | 1 |
| Shen, Y | 2 |
| Chen, W | 2 |
| Kulikova, AA | 1 |
| Cheglakov, IB | 1 |
| Kukharsky, MS | 1 |
| Ovchinnikov, RK | 1 |
| Gueto-Tettay, C | 1 |
| Pestana-Nobles, R | 1 |
| Drosos-Ramirez, JC | 1 |
| Voevodskaya, O | 1 |
| Sundgren, PC | 1 |
| Strandberg, O | 1 |
| Zetterberg, H | 1 |
| Minthon, L | 1 |
| Blennow, K | 1 |
| Wahlund, LO | 1 |
| Westman, E | 1 |
| Hansson, O | 1 |
| Zhang, D | 1 |
| Mably, AJ | 1 |
| Walsh, DM | 1 |
| Rowan, MJ | 1 |
| Su, L | 1 |
| Blamire, AM | 1 |
| Watson, R | 1 |
| Hayes, L | 1 |
| O'Brien, JT | 2 |
| Gu, T | 1 |
| Wu, WY | 1 |
| Dong, ZX | 1 |
| Yu, SP | 1 |
| Sun, Y | 1 |
| Zhong, Y | 1 |
| Lu, YT | 1 |
| Li, NG | 1 |
| Tsvetkov, PO | 1 |
| Popov, IA | 1 |
| Nikolaev, EN | 1 |
| Archakov, AI | 1 |
| García Santos, JM | 1 |
| Gavrila, D | 1 |
| Antúnez, C | 1 |
| Tormo, MJ | 1 |
| Salmerón, D | 1 |
| Carles, R | 1 |
| Jiménez Veiga, J | 1 |
| Parrilla, G | 1 |
| Torres del Río, S | 1 |
| Fortuna, L | 1 |
| Navarro, C | 1 |
| Griffith, HR | 2 |
| den Hollander, JA | 2 |
| Okonkwo, OC | 1 |
| O'Brien, T | 1 |
| Watts, RL | 1 |
| Marson, DC | 2 |
| Thambisetty, M | 1 |
| Hye, A | 1 |
| Foy, C | 1 |
| Daly, E | 2 |
| Glover, A | 2 |
| Cooper, A | 1 |
| Simmons, A | 3 |
| Murphy, D | 1 |
| Lovestone, S | 3 |
| Wang, Z | 1 |
| Zhao, C | 1 |
| Yu, L | 1 |
| Zhou, W | 1 |
| Li, K | 1 |
| Lais, C | 1 |
| Rochmont, Adu M | 1 |
| Kratzsch, T | 1 |
| Frölich, L | 3 |
| Maurer, K | 1 |
| Zanella, FE | 1 |
| Lanfermann, H | 1 |
| Pantel, J | 1 |
| Jessen, F | 8 |
| Gür, O | 2 |
| Block, W | 9 |
| Ende, G | 2 |
| Hammen, T | 2 |
| Wiltfang, J | 3 |
| Kucinski, T | 2 |
| Jahn, H | 1 |
| Heun, R | 6 |
| Maier, W | 4 |
| Kölsch, H | 1 |
| Kornhuber, J | 2 |
| Träber, F | 7 |
| Wang, PN | 1 |
| Lee, HC | 1 |
| Wang, CH | 1 |
| Ping, YH | 1 |
| Liu, TY | 1 |
| Chi, CW | 1 |
| Lin, KN | 1 |
| Liu, HC | 2 |
| Yang, H | 2 |
| Fung, EY | 1 |
| Zubarev, AR | 1 |
| Zubarev, RA | 2 |
| Park, SA | 1 |
| Shaked, GM | 1 |
| Bredesen, DE | 5 |
| Koo, EH | 2 |
| Labak, M | 1 |
| Foniok, T | 1 |
| Kirk, D | 1 |
| Rushforth, D | 1 |
| Tomanek, B | 1 |
| Jasiński, A | 1 |
| Grieb, P | 1 |
| Rupsingh, R | 2 |
| Smith, M | 2 |
| Modrego, PJ | 4 |
| Fayed, N | 4 |
| Errea, JM | 1 |
| Rios, C | 1 |
| Pina, MA | 2 |
| Sarasa, M | 1 |
| Hureau, C | 1 |
| Coppel, Y | 2 |
| Dorlet, P | 1 |
| Solari, PL | 1 |
| Sayen, S | 1 |
| Guillon, E | 1 |
| Sabater, L | 1 |
| Faller, P | 2 |
| Xu, W | 1 |
| Zhan, Y | 1 |
| Huang, W | 5 |
| Zhang, S | 1 |
| Lei, H | 2 |
| Schieb, H | 1 |
| Weidlich, S | 1 |
| Schlechtingen, G | 1 |
| Linning, P | 1 |
| Jennings, G | 1 |
| Gruner, M | 1 |
| Klafki, HW | 1 |
| Knölker, HJ | 1 |
| Foy, CM | 1 |
| Daly, EM | 1 |
| O'Gorman, R | 1 |
| Murphy, DG | 1 |
| Quintanilla, RA | 1 |
| Dolan, PJ | 1 |
| Jin, YN | 1 |
| Johnson, GV | 1 |
| Lamar, M | 1 |
| Foy, CML | 1 |
| Beacher, F | 1 |
| Poppe, M | 1 |
| Archer, N | 1 |
| Prasher, V | 1 |
| Murphy, KC | 1 |
| Morris, RG | 1 |
| Murphy, DGM | 1 |
| Wang, T | 2 |
| Xiao, S | 1 |
| Li, X | 1 |
| Ding, B | 1 |
| Ling, H | 1 |
| Chen, K | 1 |
| Lyutvinskiy, Y | 1 |
| Soininen, H | 1 |
| Lewczuk, P | 1 |
| Arlt, S | 1 |
| Popp, J | 1 |
| Peters, O | 1 |
| Majer, E | 1 |
| Rojas-Salinas, G | 1 |
| Aguilar, K | 1 |
| Ashford, JW | 1 |
| Adamson, M | 1 |
| Beale, T | 1 |
| La, D | 1 |
| Hernandez, B | 1 |
| Noda, A | 1 |
| Rosen, A | 1 |
| O'Hara, R | 1 |
| Fairchild, JK | 1 |
| Spielman, D | 1 |
| Yesavage, JA | 1 |
| Hall, H | 1 |
| Cuellar-Baena, S | 1 |
| Dahlberg, C | 1 |
| In't Zandt, R | 1 |
| Denisov, V | 1 |
| Kirik, D | 1 |
| Walecki, J | 1 |
| Barcikowska, M | 1 |
| Ćwikła, JB | 1 |
| Gabryelewicz, T | 1 |
| Forster, DM | 1 |
| James, MF | 1 |
| Williams, SR | 1 |
| Silveira de Souza, A | 1 |
| de Oliveira-Souza, R | 1 |
| Moll, J | 1 |
| Tovar-Moll, F | 1 |
| Andreiuolo, PA | 1 |
| Bottino, CM | 3 |
| Shahpasand, K | 1 |
| Uemura, I | 1 |
| Saito, T | 1 |
| Asano, T | 1 |
| Hata, K | 1 |
| Shibata, K | 1 |
| Toyoshima, Y | 1 |
| Hasegawa, M | 1 |
| Hisanaga, S | 1 |
| Mlynárik, V | 1 |
| Cacquevel, M | 1 |
| Sun-Reimer, L | 1 |
| Janssens, S | 1 |
| Cudalbu, C | 1 |
| Schneider, BL | 1 |
| Aebischer, P | 1 |
| Gruetter, R | 1 |
| Lim, TS | 2 |
| Hong, YH | 2 |
| Choi, JY | 2 |
| Kim, HS | 2 |
| Moon, SY | 2 |
| Chen, WT | 1 |
| Hong, CJ | 1 |
| Lin, YT | 1 |
| Chang, WH | 1 |
| Huang, HT | 1 |
| Liao, JY | 1 |
| Chang, YJ | 1 |
| Hsieh, YF | 1 |
| Cheng, CY | 1 |
| Chen, YR | 1 |
| Cheng, IH | 1 |
| Lee, HY | 1 |
| Chen, SQ | 1 |
| Cai, Q | 1 |
| Shen, YY | 1 |
| Wang, PJ | 2 |
| Teng, GJ | 1 |
| Zang, FC | 1 |
| Nilsen, LH | 1 |
| Melø, TM | 1 |
| Saether, O | 1 |
| Witter, MP | 1 |
| Sonnewald, U | 1 |
| Algarzae, N | 1 |
| Hebron, M | 1 |
| Miessau, M | 1 |
| Moussa, CE | 1 |
| Haris, M | 1 |
| Singh, A | 1 |
| Cai, K | 1 |
| Nath, K | 1 |
| Crescenzi, R | 1 |
| Kogan, F | 1 |
| Hariharan, H | 1 |
| Reddy, R | 1 |
| Li, MH | 1 |
| Wang, GL | 1 |
| Li, P | 1 |
| Gao, XL | 1 |
| van Duijn, S | 1 |
| Nabuurs, RJ | 1 |
| van Duinen, SG | 1 |
| Natté, R | 1 |
| van Buchem, MA | 1 |
| Alia, A | 1 |
| Güttler, BH | 1 |
| Cynis, H | 1 |
| Seifert, F | 1 |
| Ludwig, HH | 1 |
| Porzel, A | 1 |
| Schilling, S | 1 |
| Firbank, MJ | 1 |
| Harrison, RM | 1 |
| Kaether, C | 1 |
| Lammich, S | 1 |
| Edbauer, D | 1 |
| Ertl, M | 1 |
| Rietdorf, J | 1 |
| Capell, A | 1 |
| Steiner, H | 2 |
| Haass, C | 3 |
| Catani, M | 3 |
| Mecocci, P | 3 |
| Tarducci, R | 4 |
| Howard, R | 2 |
| Pelliccioli, GP | 3 |
| Mariani, E | 1 |
| Metastasio, A | 1 |
| Benedetti, C | 1 |
| Senin, U | 4 |
| Cherubini, A | 3 |
| Flacke, S | 4 |
| Pohl, C | 1 |
| Schild, H | 2 |
| Shimizu, T | 3 |
| Fukuda, H | 2 |
| Murayama, S | 1 |
| Izumiyama, N | 1 |
| Shirasawa, T | 5 |
| Cheng, LL | 1 |
| Newell, K | 1 |
| Mallory, AE | 1 |
| Hyman, BT | 1 |
| Gonzalez, RG | 1 |
| Piccirilli, M | 2 |
| Sciarma, T | 1 |
| Gobbi, G | 3 |
| Pelliccioli, G | 1 |
| Petrillo, SM | 1 |
| Weiss, U | 1 |
| Bacher, R | 1 |
| Vonbank, H | 1 |
| Kemmler, G | 1 |
| Lingg, A | 1 |
| Marksteiner, J | 1 |
| Baslow, MH | 1 |
| Suckow, RF | 1 |
| Gaynor, K | 1 |
| Bhakoo, KK | 1 |
| Marks, N | 1 |
| Saito, M | 2 |
| Duff, K | 1 |
| Matsuoka, Y | 1 |
| Berg, MJ | 1 |
| Reynolds, G | 2 |
| Edland, SD | 2 |
| Ivnik, RJ | 4 |
| Tangalos, EG | 4 |
| Waldman, AD | 3 |
| Rai, GS | 1 |
| Gamblin, TC | 1 |
| Chen, F | 2 |
| Zambrano, A | 1 |
| Abraha, A | 1 |
| Lagalwar, S | 1 |
| Guillozet, AL | 1 |
| Lu, M | 1 |
| Fu, Y | 2 |
| LaPointe, N | 1 |
| Miller, R | 1 |
| Berry, RW | 3 |
| Cryns, VL | 2 |
| Schuff, N | 4 |
| Capizzano, AA | 2 |
| Du, AT | 2 |
| Amend, DL | 3 |
| O'Neill, J | 2 |
| Norman, D | 7 |
| Jagust, WJ | 2 |
| Chui, HC | 1 |
| Kramer, JH | 2 |
| Reed, BR | 1 |
| Miller, BL | 2 |
| Yaffe, K | 2 |
| Weiner, MW | 7 |
| Westphalen, RI | 1 |
| Scott, HL | 2 |
| Dodd, PR | 3 |
| Krishnan, KR | 3 |
| Charles, HC | 4 |
| Doraiswamy, PM | 3 |
| Mintzer, J | 1 |
| Weisler, R | 1 |
| Yu, X | 1 |
| Perdomo, C | 1 |
| Ieni, JR | 1 |
| Rogers, S | 1 |
| Kizu, O | 1 |
| Yamada, K | 1 |
| Ito, H | 1 |
| Nishimura, T | 1 |
| Jones, RS | 1 |
| Tang-Wai, DF | 1 |
| O'Brien, PC | 3 |
| Frederick, BD | 1 |
| Lyoo, IK | 1 |
| Satlin, A | 2 |
| Ahn, KH | 1 |
| Kim, MJ | 1 |
| Yurgelun-Todd, DA | 2 |
| Cohen, BM | 1 |
| Renshaw, PF | 2 |
| von Kienlin, M | 1 |
| Künnecke, B | 1 |
| Metzger, F | 1 |
| Steiner, G | 1 |
| Richards, JG | 1 |
| Ozmen, L | 1 |
| Jacobsen, H | 1 |
| Loetscher, H | 1 |
| Guillozet-Bongaarts, AL | 3 |
| Reynolds, MR | 2 |
| Horowitz, PM | 1 |
| Cahill, ME | 2 |
| Bigio, EH | 1 |
| Hancu, I | 1 |
| Zimmerman, EA | 1 |
| Sailasuta, N | 1 |
| Hurd, RE | 1 |
| Falini, A | 1 |
| Bozzali, M | 1 |
| Magnani, G | 1 |
| Pero, G | 1 |
| Gambini, A | 1 |
| Benedetti, B | 1 |
| Mossini, R | 1 |
| Franceschi, M | 1 |
| Comi, G | 1 |
| Scotti, G | 1 |
| Filippi, M | 1 |
| Ntais, C | 1 |
| Polycarpou, A | 1 |
| Maestú, F | 1 |
| García-Segura, J | 1 |
| Ortiz, T | 1 |
| Montoya, J | 1 |
| Fernández, A | 1 |
| Gil-Gregorio, P | 1 |
| Campo, P | 1 |
| Fernández, S | 1 |
| Viaño, J | 1 |
| Portera, A | 1 |
| Traeber, F | 2 |
| Freymann, N | 1 |
| Schild, HH | 5 |
| D'Aniello, A | 4 |
| Fisher, G | 1 |
| Migliaccio, N | 1 |
| Cammisa, G | 1 |
| D'Aniello, E | 1 |
| Spinelli, P | 1 |
| Engelhardt, E | 2 |
| Moreira, DM | 2 |
| Laks, J | 2 |
| Cavalcanti, JL | 1 |
| Madeira, A | 1 |
| Pommet, JM | 1 |
| Prochiantz, A | 1 |
| Allinquant, B | 1 |
| Yin, H | 1 |
| Kuret, J | 1 |
| Azevedo, D | 2 |
| Tatsch, M | 2 |
| Hototian, SR | 2 |
| Bazzarella, MC | 2 |
| Castro, CC | 2 |
| Mihara, M | 1 |
| Hattori, N | 2 |
| Abe, K | 2 |
| Sakoda, S | 2 |
| Sawada, T | 2 |
| Galvan, V | 4 |
| Gorostiza, OF | 3 |
| Banwait, S | 4 |
| Ataie, M | 3 |
| Logvinova, AV | 1 |
| Sitaraman, S | 1 |
| Carlson, E | 1 |
| Sagi, SA | 1 |
| Chevallier, N | 1 |
| Jin, K | 1 |
| Greenberg, DA | 1 |
| Harris, K | 1 |
| Lin, A | 1 |
| Bhattacharya, P | 1 |
| Tran, T | 1 |
| Wong, W | 1 |
| Ross, B | 1 |
| Reyes, D | 1 |
| Shiung, M | 1 |
| Freymann, K | 1 |
| Guilloreau, L | 1 |
| Damian, L | 1 |
| Mazarguil, H | 1 |
| Winterhalter, M | 1 |
| Garrard, P | 1 |
| Schott, JM | 1 |
| MacManus, DG | 1 |
| Hodges, JR | 1 |
| Fox, NC | 1 |
| Hu, L | 2 |
| Yue, Y | 2 |
| Zuo, PP | 2 |
| Jin, ZY | 2 |
| Feng, F | 1 |
| You, H | 1 |
| Li, ML | 1 |
| Ge, QS | 2 |
| Stewart, CC | 1 |
| Evanochko, WT | 1 |
| Buchthal, SD | 1 |
| Harrell, LE | 1 |
| Zamrini, EY | 1 |
| Brockington, JC | 1 |
| Karr, JW | 1 |
| Szalai, VA | 1 |
| Tian, QJ | 1 |
| Jiang, JM | 1 |
| Dong, YL | 1 |
| Cheng, YH | 1 |
| Hong, X | 1 |
| Rami, L | 1 |
| Gómez-Ansón, B | 1 |
| Bosch, B | 1 |
| Sánchez-Valle, R | 1 |
| Monte, GC | 1 |
| Villar, A | 1 |
| Molinuevo, JL | 1 |
| Okada, T | 1 |
| Sakamoto, S | 1 |
| Nakamoto, Y | 1 |
| Kohara, N | 1 |
| Senda, M | 1 |
| Nguyen, TV | 1 |
| Tang, H | 2 |
| Ghosh, AK | 1 |
| Kumaragurubaran, N | 1 |
| Hong, L | 1 |
| Kulkarni, S | 1 |
| Xu, X | 1 |
| Miller, HB | 1 |
| Reddy, DS | 1 |
| Weerasena, V | 1 |
| Turner, R | 1 |
| Chang, W | 1 |
| Koelsch, G | 1 |
| Tang, J | 1 |
| Wang, B | 1 |
| Tan, S | 1 |
| Yang, Z | 1 |
| Xie, YC | 1 |
| Wang, J | 1 |
| Zhou, S | 1 |
| Li, S | 1 |
| Zheng, C | 1 |
| Ma, X | 1 |
| Rylett, J | 1 |
| Crippen, D | 1 |
| Basurto-Islas, G | 1 |
| Smith, CC | 2 |
| Bowen, DM | 7 |
| Sims, NR | 1 |
| Neary, D | 3 |
| Davison, AN | 1 |
| Perry, EK | 4 |
| Atack, JR | 1 |
| Perry, RH | 4 |
| Hardy, JA | 1 |
| Edwardson, JA | 1 |
| Blessed, G | 2 |
| Tomlinson, BE | 2 |
| Fairbairn, AF | 1 |
| Tarbit, I | 1 |
| Arias, C | 1 |
| Arrieta, I | 1 |
| Tapia, R | 1 |
| Constans, JM | 3 |
| Meyerhoff, DJ | 4 |
| Gerson, J | 1 |
| MacKay, S | 3 |
| Fein, G | 5 |
| Kuhl, CK | 1 |
| Fric, M | 1 |
| Keller, E | 4 |
| Lamerichs, R | 4 |
| Rink, H | 1 |
| Möller, HJ | 1 |
| Shonk, T | 3 |
| Kwo-On-Yuen, PF | 1 |
| Newmark, RD | 1 |
| Budinger, TF | 1 |
| Kaye, JA | 1 |
| Ball, MJ | 2 |
| Jaarsma, D | 1 |
| Veenma-van der Duin, L | 1 |
| Korf, J | 2 |
| Tannenberg, AE | 1 |
| Mohanakrishnan, P | 2 |
| Fowler, AH | 2 |
| Vonsattel, JP | 3 |
| Husain, MM | 2 |
| Jolles, PR | 2 |
| Liem, P | 2 |
| Komoroski, RA | 2 |
| Mori, H | 5 |
| Ishii, K | 1 |
| Tomiyama, T | 2 |
| Furiya, Y | 2 |
| Sahara, N | 1 |
| Asano, S | 2 |
| Endo, N | 2 |
| Takio, K | 2 |
| Christiansen, P | 1 |
| Schlosser, A | 1 |
| Henriksen, O | 1 |
| Kenessey, A | 1 |
| Yen, SH | 1 |
| Liu, WK | 1 |
| Yang, XR | 1 |
| Dunlop, DS | 1 |
| Resnick, SM | 1 |
| Costa, PT | 1 |
| Shonk, TK | 1 |
| Moats, RA | 3 |
| Gifford, P | 1 |
| Michaelis, T | 1 |
| Mandigo, JC | 1 |
| Izumi, J | 1 |
| Van Dyke, C | 1 |
| Miulli, DE | 1 |
| Norwell, DY | 1 |
| Schwartz, FN | 1 |
| Holmes, C | 1 |
| Webster, MT | 1 |
| Procter, AW | 4 |
| Francis, PT | 4 |
| Matsuda, M | 1 |
| Morikawa, S | 1 |
| Inubushi, T | 1 |
| Handa, J | 1 |
| Murata, T | 2 |
| Koshino, Y | 1 |
| Omori, M | 2 |
| Murata, I | 1 |
| Nishio, M | 1 |
| Horie, T | 1 |
| Umezawa, Y | 1 |
| Isaki, K | 1 |
| Kimura, H | 2 |
| Itoh, S | 1 |
| Roher, AE | 2 |
| Lowenson, JD | 2 |
| Clarke, S | 2 |
| Wolkow, C | 1 |
| Wang, R | 1 |
| Cotter, RJ | 1 |
| Reardon, IM | 1 |
| Zürcher-Neely, HA | 1 |
| Heinrikson, RL | 1 |
| Ernst, T | 2 |
| Woolley, S | 1 |
| Tsai, G | 1 |
| Coyle, JT | 2 |
| Stewart, GR | 1 |
| Olney, JW | 3 |
| Schmidt, RE | 1 |
| Wozniak, DF | 1 |
| Lowenthal, DT | 1 |
| Presciutti, O | 1 |
| Palumbo, R | 1 |
| Chiarini, P | 1 |
| Palumbo, B | 1 |
| Csernansky, JG | 1 |
| Bardgett, ME | 1 |
| Sheline, YI | 1 |
| Morris, JC | 1 |
| Kattapong, VJ | 1 |
| Brooks, WM | 1 |
| Wesley, MH | 1 |
| Kodituwakku, PW | 1 |
| Reznik-Wolf, H | 1 |
| Treves, TA | 1 |
| Davidson, M | 1 |
| Aharon-Peretz, J | 1 |
| St George Hyslop, PH | 1 |
| Chapman, J | 1 |
| Korczyn, AD | 1 |
| Goldman, B | 1 |
| Friedman, E | 1 |
| Velazquez, P | 2 |
| Cribbs, DH | 1 |
| Poulos, TL | 1 |
| Tenner, AJ | 2 |
| Myers, L | 1 |
| Schlegel, S | 1 |
| Graf-Morgenstern, M | 1 |
| Tintera, J | 1 |
| Gawehn, J | 1 |
| Stoeter, P | 1 |
| Chang, L | 2 |
| Melchor, R | 1 |
| Mehringer, CM | 1 |
| Frederick, BB | 1 |
| Ide, M | 1 |
| Naruse, S | 1 |
| Furuya, S | 1 |
| Passani, LA | 1 |
| Carter, RE | 1 |
| Amend, D | 1 |
| Ezekiel, F | 1 |
| Steinman, SK | 1 |
| Tanabe, J | 1 |
| Jagust, W | 2 |
| Mastrianni, JA | 1 |
| Tanabe, JL | 1 |
| Laubenberger, J | 1 |
| Bayer, S | 1 |
| Thiel, T | 1 |
| Hennig, J | 1 |
| Langer, M | 1 |
| Lee, JM | 1 |
| Petrucelli, L | 2 |
| Di Fiore, MM | 1 |
| Lazeyras, F | 1 |
| Tupler, LA | 1 |
| Erickson, R | 1 |
| Boyko, OB | 1 |
| Watanabe, A | 2 |
| Ihara, Y | 1 |
| Arai, T | 1 |
| Akiyama, H | 1 |
| Ikeda, K | 1 |
| Kondo, H | 1 |
| Wolfe, MS | 1 |
| Xia, W | 1 |
| Ostaszewski, BL | 1 |
| Diehl, TS | 1 |
| Kimberly, WT | 1 |
| Selkoe, DJ | 1 |
| Nakajima, M | 1 |
| Gervais, FG | 1 |
| Xu, D | 1 |
| Robertson, GS | 1 |
| Vaillancourt, JP | 1 |
| Zhu, Y | 1 |
| Huang, J | 1 |
| LeBlanc, A | 1 |
| Smith, D | 1 |
| Rigby, M | 1 |
| Shearman, MS | 1 |
| Clarke, EE | 1 |
| Zheng, H | 1 |
| Van Der Ploeg, LH | 1 |
| Ruffolo, SC | 1 |
| Thornberry, NA | 1 |
| Xanthoudakis, S | 1 |
| Zamboni, RJ | 1 |
| Roy, S | 1 |
| Nicholson, DW | 1 |
| Fonseca, MI | 1 |
| Head, E | 1 |
| Cotman, CW | 3 |
| Leimer, U | 1 |
| Lun, K | 1 |
| Romig, H | 1 |
| Walter, J | 1 |
| Grünberg, J | 1 |
| Brand, M | 1 |
| Orpiszewski, J | 1 |
| Schormann, N | 1 |
| Kluve-Beckerman, B | 1 |
| Liepnieks, JJ | 1 |
| Benson, MD | 1 |
| Sauder, JM | 1 |
| Arthur, JW | 1 |
| Dunbrack, RL | 1 |
| Adalsteinsson, E | 1 |
| Sullivan, EV | 1 |
| Kleinhans, N | 1 |
| Spielman, DM | 1 |
| Pfefferbaum, A | 1 |
| Xu, YC | 1 |
| Campeau, NG | 1 |
| Kokmen, E | 1 |
| Harkany, T | 1 |
| Abrahám, I | 1 |
| Timmerman, W | 1 |
| Laskay, G | 1 |
| Tóth, B | 1 |
| Sasvári, M | 1 |
| Kónya, C | 1 |
| Sebens, JB | 1 |
| Nyakas, C | 1 |
| Zarándi, M | 1 |
| Soós, K | 1 |
| Penke, B | 1 |
| Luiten, PG | 1 |
| Papassotiropoulos, A | 1 |
| Ogawara, M | 1 |
| Kunugi, H | 1 |
| Akahane, A | 1 |
| Ueki, A | 1 |
| Otsuka, M | 1 |
| Isse, K | 1 |
| Hirasawa, H | 1 |
| Kato, N | 1 |
| Nabika, T | 1 |
| Kobayashi, S | 1 |
| Nanko, S | 1 |
| Chen, JG | 1 |
| Barboriak, DP | 1 |
| Yu, G | 1 |
| Nishimura, M | 1 |
| Tandon, A | 1 |
| Kawarai, T | 1 |
| Arawaka, S | 1 |
| Supala, A | 1 |
| Song, YQ | 1 |
| Rogaeva, E | 1 |
| Holmes, E | 1 |
| Zhang, DM | 1 |
| Milman, P | 1 |
| Fraser, P | 2 |
| St George-Hyslop, P | 1 |
| Sánchez-Guerra, M | 1 |
| Combarros, O | 1 |
| Alvarez-Arcaya, A | 1 |
| Mateo, I | 1 |
| Berciano, J | 1 |
| González-García, J | 1 |
| Llorca, J | 1 |
| Mielke, R | 1 |
| Schopphoff, HH | 1 |
| Kugel, H | 1 |
| Pietrzyk, U | 1 |
| Heindel, W | 1 |
| Kessler, J | 1 |
| Heiss, WD | 1 |
| Kaneko, I | 1 |
| Morimoto, K | 1 |
| Kubo, T | 1 |
| Trabace, L | 1 |
| Cassano, T | 1 |
| Cagiano, R | 1 |
| Tattoli, M | 1 |
| Pietra, C | 1 |
| Steardo, L | 1 |
| Kendrick, KM | 1 |
| Cuomo, V | 1 |
| Alexander, GE | 1 |
| Shetty, HU | 1 |
| Krasuski, JS | 1 |
| Rapoport, SI | 1 |
| Schapiro, MB | 1 |
| Katayama, T | 1 |
| Imaizumi, K | 1 |
| Honda, A | 1 |
| Yoneda, T | 1 |
| Kudo, T | 1 |
| Takeda, M | 1 |
| Mori, K | 1 |
| Rozmahel, R | 1 |
| George-Hyslop, PS | 1 |
| Tohyama, M | 1 |
| Kirkitadze, MD | 1 |
| Condron, MM | 1 |
| Teplow, DB | 1 |
| Lleó, A | 1 |
| Blesa, R | 1 |
| Gendre, J | 1 |
| Castellví, M | 1 |
| Pastor, P | 1 |
| Queralt, R | 1 |
| Oliva, R | 1 |
| Marinho, VM | 1 |
| Rozenthal, M | 1 |
| Oliveira, AC | 1 |
| Kado, H | 1 |
| Kosaka, H | 1 |
| Iidaka, T | 1 |
| Itoh, H | 1 |
| Wada, Y | 1 |
| Kramer, J | 1 |
| Miller, B | 1 |
| Wolkowitz, OM | 1 |
| Manka, C | 1 |
| Klunk, WE | 1 |
| Panchalingam, K | 1 |
| Moossy, J | 1 |
| McClure, RJ | 1 |
| Pettegrew, JW | 1 |
| Fisher, GH | 5 |
| Vetere, A | 2 |
| Cusano, GP | 2 |
| Chávez, M | 1 |
| Payan, IL | 3 |
| Chou, SJ | 2 |
| Man, EH | 4 |
| Emory, C | 2 |
| Frey, WH | 3 |
| Cerwinski, S | 1 |
| Martin, T | 1 |
| Padula, L | 1 |
| Xuereb, JH | 1 |
| Candy, JM | 1 |
| Marshall, E | 1 |
| Bonham, JR | 1 |
| Ninomiya, H | 1 |
| Fukunaga, R | 1 |
| Taniguchi, T | 1 |
| Fujiwara, M | 1 |
| Shimohama, S | 1 |
| Kameyama, M | 1 |
| Chalmers, DT | 1 |
| Dewar, D | 1 |
| Graham, DI | 1 |
| Brooks, DN | 1 |
| McCulloch, J | 1 |
| Cross, AJ | 2 |
| Slater, P | 2 |
| Simpson, M | 1 |
| Royston, C | 1 |
| Deakin, JF | 2 |
| Simpson, MD | 1 |
| Royston, MC | 1 |
| Mann, DM | 1 |
| Meldrum, B | 1 |
| Snowden, JS | 1 |
| De Boni, U | 1 |
| McLachlan, DR | 1 |
| Sasaki, H | 1 |
| Muramoto, O | 1 |
| Kanazawa, I | 1 |
| Kosaka, K | 1 |
| Iizuka, R | 1 |
| Geddes, JW | 1 |
| Ellison, DW | 1 |
| Beal, MF | 1 |
| Mazurek, MF | 1 |
| Bird, ED | 1 |
| Martin, JB | 1 |
| Greenamyre, JT | 1 |
| Penney, JB | 1 |
| D'Amato, CJ | 1 |
| Young, AB | 1 |
| Hardy, J | 3 |
| Cowburn, R | 3 |
| Barton, A | 1 |
| Lofdahl, E | 1 |
| O'Carroll, AM | 1 |
| Wester, P | 1 |
| Winblad, B | 1 |
| Carl, R | 1 |
| Pearson, A | 1 |
| Lowe, SL | 2 |
| Neal, JW | 1 |
| Stephens, PH | 1 |
| Powell, TP | 1 |
| Palmer, AM | 3 |
| Murphy, E | 1 |
| Roberts, P | 2 |
| Briggs, R | 2 |
| Esiri, MM | 1 |
| Stratmann, GC | 2 |
| Najlerahim, A | 1 |
| Patel, AJ | 1 |
| Hunt, A | 1 |
| Monaghan, DT | 1 |
| Shapira, R | 1 |
| Austin, GE | 1 |
| Mirra, SS | 1 |
| Cadilla-Perezrios, R | 1 |
| Garcia, NM | 1 |
| Chemburkar, R | 1 |
| Arends, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Swedish BioFINDER Study: Early Diagnosis of Alzheimer's Disease - a Multidisciplinary Approach[NCT01208675] | 1,150 participants (Actual) | Observational | 2010-09-30 | Active, not recruiting | |||
| Memantine Versus Donepezil in Mild to Moderate Alzheimer's Disease. A Randomized Trial With Magnetic Resonance Spectroscopy.[NCT00505167] | Phase 4 | 64 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| In Vivo Investigation on Mitochondrial Dysfunction in Post-COVID Fatigue and Cancer Fatigue.[NCT05753228] | 90 participants (Anticipated) | Interventional | 2022-12-09 | Recruiting | |||
| An Open-label Exploratory Study With Memantine: Correlation Between Proton Magnetic Resonance Spectroscopy, Cerebrospinal Fluid Biomarkers, and Cognition in Patients With Mild to Moderate Alzheimer's Disease[NCT00551161] | Phase 4 | 12 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in the Brains of Healthy Controls and Patients With Dementia.[NCT05374278] | Phase 1/Phase 2 | 102 participants (Anticipated) | Interventional | 2021-11-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Ratios of myo-inositol (mI), N-acetylaspartate (NAA), total creatine (Cr), and choline (Cho) by single voxel 1H MRS (proton magnetic resonance spectroscopy). Mean (± SD) metabolite levels (normalized to T2-corrected water signal intensity) and metabolite ratios for Alzheimer's disease subjects at baseline (t0), after 24 weeks of ongoing monotherapy with stable-dose cholinesterase inhibitor (t1), and after another 24 weeks of combination therapy with memantine in addition to stable-dose cholinesterase inhibitor (t2). The Wilcoxon signed-rank test was used to examine whether the change between t0 and t1 differed from the change between t1 and t2 [(t2 - t1) - (t1 - t0)]. (NCT00551161)
Timeframe: Baseline, 24 weeks, and 48 weeks
| Intervention | ratio (normalized to T2-corrected water (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change in NAA [(t2-t1) - (t1-t0)] | Change in Cr [(t2-t1) - (t1-t0)] | Change in Cho [(t2-t1) - (t1-t0)] | Change in mI [(t2-t1) - (t1-t0)] | Change in NAA/Cr [(t2-t1) - (t1-t0)] | Change in Cho/Cr [(t2-t1) - (t1-t0)] | Change in mI/Cr [(t2-t1) - (t1-t0)] | Change in NAA/Cho [(t2-t1) - (t1-t0)] | Change in NAA/mI [(t2-t1) - (t1-t0)] | |
| Memantine | -54 | -2 | 9 | 16 | -0.09 | 0.02 | 0.04 | -0.26 | -0.35 |
14 reviews available for aspartic acid and Alzheimer Disease
| Article | Year |
|---|---|
The contributions of metabolomics in the discovery of new therapeutic targets in Alzheimer's disease.
Topics: Alanine; Alzheimer Disease; Animals; Arginine; Aspartic Acid; Biomarkers; Disease Models, Animal; Gl | 2021 |
The Role of D-Amino Acids in Alzheimer's Disease.
Topics: Alzheimer Disease; Amino Acids; Animals; Aspartic Acid; Humans; Receptors, N-Methyl-D-Aspartate; Ser | 2021 |
Proton MRS in mild cognitive impairment.
Topics: Alzheimer Disease; Animals; Aspartic Acid; Biomarkers; Brain; Choline; Cognitive Dysfunction; Creati | 2013 |
Magnetic Resonance Spectroscopy in Alzheimer's Disease: Systematic Review and Meta-Analysis.
Topics: Alzheimer Disease; Aspartic Acid; Brain; Creatine; Databases, Bibliographic; Humans; Magnetic Resona | 2015 |
Development and Structural Modification of BACE1 Inhibitors.
Topics: Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Aspartic | 2016 |
A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease.
Topics: Alzheimer Disease; Aspartic Acid; Brain; Choline; Humans; Inositol; Magnetic Resonance Spectroscopy; | 2002 |
1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia.
Topics: Acetylcholine; Alzheimer Disease; Aspartic Acid; Cerebral Cortex; Dementia, Vascular; Glutamic Acid; | 2004 |
Association of the endothelial nitric oxide synthase (NOS3) Glu298Asp gene polymorphism with the risk of Alzheimer's disease-- a meta-analysis.
Topics: Alleles; Alzheimer Disease; Asian People; Aspartic Acid; Case-Control Studies; Confidence Intervals; | 2005 |
N-acetylaspartate in neuropsychiatric disorders.
Topics: Alzheimer Disease; Aspartic Acid; Brain; Neuropsychology | 1995 |
Isoaspartate formation and neurodegeneration in Alzheimer's disease.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Animals; Aspartic Acid; Blood Vessels | 2000 |
Magnetic resonance spectroscopy in Alzheimer's disease: focus on N-acetylaspartate.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Autopsy; Diagnosis, Differential; Humans; Magnetic Resonance | 2000 |
[Alzheimer's disease and magnetic resonance spectroscopy of the hippocampus].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Case-Control Studies; Choline; Creatine; | 2001 |
Excitotoxin-mediated neuron death in youth and old age.
Topics: Aging; Alzheimer Disease; Amino Acids; Animals; Aspartic Acid; Brain Diseases, Metabolic; Brain Inju | 1990 |
Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters.
Topics: Alzheimer Disease; Animals; Aspartic Acid; Basal Ganglia Diseases; Brain; Brain Ischemia; Epilepsy; | 1985 |
13 trials available for aspartic acid and Alzheimer Disease
| Article | Year |
|---|---|
Effect of the Tottori familial disease mutation (D7N) on the monomers and dimers of Aβ40 and Aβ42.
Topics: Alzheimer Disease; Amination; Amyloid beta-Peptides; Asparagine; Aspartic Acid; Humans; Hydrogen-Ion | 2013 |
3.0 T MRI arterial spin labeling and magnetic resonance spectroscopy technology in the application of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Biomarkers; Case-Control Studies; Cerebrovascular Circulatio | 2014 |
Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition Disorders; Crea | 2008 |
Absolute quantification in proton magnetic resonance spectroscopy is superior to relative ratio to discriminate Alzheimer's disease from Binswanger's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Creatine; Dementia, Vascular; Diagnosis, Differenti | 2008 |
Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain Mapping; Choline; Cholinesterase In | 2010 |
Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Cholinesterase Inhibitors; Donepez | 2010 |
MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain Mapping; Creatine; Double-Blind Met | 2011 |
Different patterns of N-acetylaspartate loss in subcortical ischemic vascular dementia and AD.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Dementia, Vascular; Diagnosis, Differential; Female; | 2003 |
Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Biomarkers; Brain Chemistry; Cholinesterase Inhibitors; Done | 2003 |
High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Choline; Cholinesterase | 2008 |
Proton spectroscopy in Alzheimer's disease and cognitive impairment no dementia: a community-based study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Atrophy; Brain; Choline; Cognition Disord | 2008 |
Probable Alzheimer disease: diagnosis with proton MR spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Diseases, Metabolic; Creatine; Dementia; Diagno | 1995 |
In vivo proton magnetic resonance spectroscopy of Alzheimer's disease in the parietal and temporal lobes.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain Mapping; Female; Humans; Magnetic R | 1997 |
253 other studies available for aspartic acid and Alzheimer Disease
| Article | Year |
|---|---|
Relationships between frontal metabolites and Alzheimer's disease biomarkers in cognitively normal older adults.
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Aspartic Acid; Biomarkers; Cognition; Creatine; Fem | 2022 |
The Auditory Afferent Pathway as a Clinical Marker of Alzheimer's Disease.
Topics: Acoustic Stimulation; Afferent Pathways; Aged; Alzheimer Disease; Aspartic Acid; Biomarkers; Cerebra | 2022 |
Beyond Protein Sequence: Protein Isomerization in Alzheimer's Disease.
Topics: Alzheimer Disease; Amino Acid Sequence; Aspartic Acid; Humans; Isomerism | 2022 |
Aspartic Acid-Modified Phospholipids Regulate Cell Response and Rescue Memory Deficits in APP/PS1 Transgenic Mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Br | 2022 |
Topics: Aged; Alzheimer Disease; Aspartic Acid; Cognition; Cognitive Dysfunction; Creatine; Glutamic Acid; H | 2022 |
Specific Mutations near the Amyloid Precursor Protein Cleavage Site Increase γ-Secretase Sensitivity and Modulate Amyloid-β Production.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2023 |
Chiral Amino Acid Profiling in Serum Reveals Potential Biomarkers for Alzheimer's Disease.
Topics: Alzheimer Disease; Amino Acids; Aspartic Acid; Biomarkers; D-Aspartic Acid; Humans; Neurodegenerativ | 2023 |
Variable fragmentation and ionization of amyloid-beta epimers and isomers.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Aspartic Acid; Humans; Isomerism; Peptide Fragments; Tande | 2023 |
[Effect of aqueous extract of Corni Fructus on Aβ_(25-35)-induced brain injury and neuroinflammation in mice with Alzheimer's disease].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Aspartic Acid; Brain Injuries; Cornus; Cysteine; | 2023 |
The role of isoaspartate in fibrillation and its prevention by Protein-L-isoaspartyl methyltransferase.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Anticonvulsants; Aspartic Acid; Benzothi | 2020 |
Amyloid beta oligomers: how pH influences over trimer and pentamer structures?
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Aspartic Acid; Histidine; Humans; Hyd | 2019 |
Complete identification of all 20 relevant epimeric peptides in β-amyloid: a new HPLC-MS based analytical strategy for Alzheimer's research.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Aspartic Acid; Chromatography, High P | 2020 |
Reduced Hippocampal Glutamate and Posterior Cingulate N-Acetyl Aspartate in Mild Cognitive Impairment and Alzheimer's Disease Is Associated with Episodic Memory Performance and White Matter Integrity in the Cingulum: A Pilot Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Cognitive Dysfunction; Diffusion Tensor I | 2020 |
Amyloid Fibril-Induced Astrocytic Glutamate Transporter Disruption Contributes to Complement C1q-Mediated Microglial Pruning of Glutamatergic Synapses.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Aspartic Acid; Astrocytes; CA1 Region, Hippocampa | 2020 |
Improvement of neuronal integrity with methylphenidate treatment for apathy in Alzheimer's disease.
Topics: Affective Symptoms; Aged; Alzheimer Disease; Apathy; Aspartic Acid; Brain; Brain Chemistry; Central | 2020 |
A Dietary Ketone Ester Normalizes Abnormal Behavior in a Mouse Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Aspartic Acid; Brain; Citric Acid Cycle; Diet; Disease Models, Animal; E | 2020 |
Identification of novel class I and class IIb histone deacetylase inhibitor for Alzheimer's disease therapeutics.
Topics: Alzheimer Disease; Aspartic Acid; Databases, Chemical; Drug Evaluation, Preclinical; Glycine; Histon | 2020 |
Cerebrospinal fluid and serum d-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Aspartic Acid; Biomarkers; Brain; | 2020 |
Autosomal dominant VCP hypomorph mutation impairs disaggregation of PHF-tau.
Topics: Alzheimer Disease; Animals; Aspartic Acid; Gene Knock-In Techniques; Genes, Dominant; Glycine; Human | 2020 |
Serum D-serine levels are altered in early phases of Alzheimer's disease: towards a precocious biomarker.
Topics: Alzheimer Disease; Amino Acids; Aspartic Acid; Biomarkers; Humans; Receptors, N-Methyl-D-Aspartate; | 2021 |
Long-Term Caloric Restriction Attenuates β-Amyloid Neuropathology and Is Accompanied by Autophagy in APPswe/PS1delta9 Mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animal Nutritional Physiological Phenomena; Animals; Aspar | 2021 |
Identification of the gene that codes for the σ
Topics: Alzheimer Disease; Animals; Aspartic Acid; Carrier Proteins; Cattle; Cholesterol; Endoplasmic Reticu | 2017 |
APPswe/PS1dE9 mice with cortical amyloid pathology show a reduced NAA/Cr ratio without apparent brain atrophy: A MRS and MRI study.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Brain; Creatine; | 2017 |
Identification of new BACE1 inhibitors using Pharmacophore and Molecular dynamics simulations approach.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Aspartic Acid; Aspartic Acid Endopeptidases | 2017 |
NSCs promote hippocampal neurogenesis, metabolic changes and synaptogenesis in APP/PS1 transgenic mice.
Topics: Alzheimer Disease; Animals; Aspartic Acid; Cognition Disorders; Creatine; Disease Models, Animal; Gl | 2017 |
Decreased N-Acetyl Aspartate/Myo-Inositol Ratio in the Posterior Cingulate Cortex Shown by Magnetic Resonance Spectroscopy May Be One of the Risk Markers of Preclinical Alzheimer's Disease: A 7-Year Follow-Up Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Biomarkers; Cognitive Dysfunction; Diseas | 2017 |
Association between altered neurochemical metabolites and apathy in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apathy; Aspartic Acid; Creatine; Female; Gyrus Cinguli; | 2018 |
Proposed biochemistry of Parkinson's and Alzheimer's diseases.
Topics: Aldehydes; Alzheimer Disease; Aspartic Acid; Betaine; Brain; Disease Progression; Humans; Kynurenine | 2017 |
Identification of ᴅ-amino acid-containing peptides in human serum.
Topics: Adult; Alzheimer Disease; Amino Acids; Aspartic Acid; Biomarkers; Cataract; Chromatography, Liquid; | 2017 |
Amyloid-β with isomerized Asp7 cytotoxicity is coupled to protein phosphorylation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Apoptosis; Aspartic Acid; Cell Line, Tumor; Cell Survival; | 2018 |
Pseudo-phosphorylation at AT8 epitopes regulates the tau truncation at aspartate 421.
Topics: Alzheimer Disease; Aspartic Acid; Caspases; Cell Line, Tumor; Epitopes; Humans; Neurons; Phosphoryla | 2018 |
The application of magnetic resonance fingerprinting to single voxel proton spectroscopy.
Topics: Adult; Alzheimer Disease; Artifacts; Aspartic Acid; Computer Simulation; Female; Gray Matter; Humans | 2018 |
Progress of Brain Amyloid Deposition in Familial Alzheimer's Disease with Taiwan D678H APP Mutation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-P | 2018 |
Isomerization of Asp7 in Beta-Amyloid Enhances Inhibition of the α7 Nicotinic Receptor and Promotes Neurotoxicity.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Amyloid beta-Peptides; Animals; Aspartic | 2019 |
Structure of amyloid-β (20-34) with Alzheimer's-associated isomerization at Asp23 reveals a distinct protofilament interface.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Aspartic Acid; Humans; Isoaspartic Ac | 2019 |
1H-MR spectroscopy metabolite levels correlate with executive function in vascular cognitive impairment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Biomarkers; Brain Ischemia; Choline; Cogn | 2013 |
Association of 1H-MR spectroscopy and cerebrospinal fluid biomarkers in Alzheimer's disease: diverging behavior at three different brain regions.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Aspartic Acid; Biomarkers; Case-Control Studies; Cho | 2013 |
Magnetic resonance imaging study cannot individually distinguish individuals with mild cognitive impairment, mild Alzheimer's disease, and normal aging.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Aspartic Acid; Choline; Cognitive Dysfunction; Di | 2013 |
Effects of Zn2+ binding on the structural and dynamic properties of amyloid β peptide associated with Alzheimer's disease: Asp1 or Glu11?
Topics: Alzheimer Disease; Amyloid beta-Peptides; Aspartic Acid; Glutamic Acid; Humans; Markov Chains; Model | 2013 |
Differences in brain metabolism associated with agitation and depression in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Creatine; Depression; Female; Gyrus Cinguli; Humans | 2013 |
1H NMR metabolomic signatures in five brain regions of the AβPPswe Tg2576 mouse model of Alzheimer's disease at four ages.
Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Biomarkers; Cerebe | 2014 |
Reversal of metabolic deficits by lipoic acid in a triple transgenic mouse model of Alzheimer's disease: a 13C NMR study.
Topics: Alzheimer Disease; Animals; Aspartic Acid; Biomarkers; Citric Acid Cycle; gamma-Aminobutyric Acid; G | 2014 |
Proteolytic cleavage of polymeric tau protein by caspase-3: implications for Alzheimer disease.
Topics: Aged, 80 and over; Alzheimer Disease; Amino Acid Chloromethyl Ketones; Aspartic Acid; Brain; Caspase | 2013 |
Altered neurochemical metabolites in Alzheimer's disease patients with unawareness of deficits.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Awareness; Creatine; Dominance, Cerebral; | 2014 |
Treatment effects in a transgenic mouse model of Alzheimer's disease: a magnetic resonance spectroscopy study after passive immunization.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Br | 2014 |
Site-specific aspartic acid isomerization regulates self-assembly and neurotoxicity of amyloid-β.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Aspartic Acid; Cell Survival; Drug Desig | 2013 |
Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Creatine; Diagnosis, Differential; Female | 2014 |
1H-proton magnetic resonance spectroscopy differentiates dementia with Lewy bodies from Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspart | 2014 |
Utility of SPM8 plus DARTEL (VSRAD) combined with magnetic resonance spectroscopy as adjunct techniques for screening and predicting dementia due to Alzheimer's disease in clinical practice.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Aspartic Acid; Brain; Choline; De | 2014 |
Comment re: Journal of the Neurological Sciences 260 (2007) 132-138, PMID 17540407.
Topics: Alzheimer Disease; Aspartic Acid; Female; Gyrus Cinguli; Humans; Inositol; Male | 2014 |
The partial volume effect in the quantification of 1H magnetic resonance spectroscopy in Alzheimer's disease and aging.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Brain; Cogni | 2014 |
A decrease in N-acetylaspartate and an increase in myoinositol in the anterior cingulate gyrus are associated with behavioral and psychological symptoms in Alzheimer's disease.
Topics: Alzheimer Disease; Aspartic Acid; Female; Gyrus Cinguli; Humans; Inositol; Male | 2014 |
Proton magnetic resonance spectroscopy in mild cognitive impairment and Alzheimer's disease: a preliminary study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Case-Control Studies; Choline; Cognitive | 2014 |
Global N-acetylaspartate in normal subjects, mild cognitive impairment and Alzheimer's disease patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Biomarkers; Brain; Cognitive Dysfunction; | 2015 |
Reduced N-acetylaspartate to creatine ratio in the posterior cingulate correlates with cognition in Alzheimer's disease following four months of rivastigmine treatment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Cholinesterase Inhibitors; Cognition Diso | 2015 |
Early Alzheimer's disease neuropathology detected by proton MR spectroscopy.
Topics: Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Aspartic Acid; Astrocytes; Biomarkers; | 2014 |
¹H- and ¹³C-NMR spectroscopy of Thy-1-APPSL mice brain extracts indicates metabolic changes in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Br | 2015 |
[Prediction of conversion from amnestic mild cognitive impairment to Alzheimer's disease using proton magnetic resonance spectroscopy].
Topics: Aged; Alzheimer Disease; Amnesia; Aspartic Acid; Cognitive Dysfunction; Disease Progression; Female; | 2015 |
A Critical Proton MR Spectroscopy Marker of Alzheimer's Disease Early Neurodegenerative Change: Low Hippocampal NAA/Cr Ratio Impacts APOE ɛ4 Mexico City Children and Their Parents.
Topics: Adolescent; Adult; Air Pollution; Alzheimer Disease; Apolipoprotein E4; Aspartic Acid; Body Mass Ind | 2015 |
Neurometabolic characteristics in the anterior cingulate gyrus of Alzheimer's disease patients with depression: a (1)H magnetic resonance spectroscopy study.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Cognition Disorders; Creatine; Depressive Disorder; Female; | 2015 |
Intracerebral Injection of Metal-Binding Domain of Aβ Comprising the Isomerized Asp7 Increases the Amyloid Burden in Transgenic Mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloidosis; Analysis of V | 2016 |
Determination of the protonation state for the catalytic dyad in β-secretase when bound to hydroxyethylamine transition state analogue inhibitors: A molecular dynamics simulation study.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Aspartic Acid; Aspar | 2016 |
Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Amyloidogenic Proteins; Apolipoprotein E4; Aspartic Acid; Brain; Brain Mapp | 2016 |
Peripheral Interventions Enhancing Brain Glutamate Homeostasis Relieve Amyloid β- and TNFα- Mediated Synaptic Plasticity Disruption in the Rat Hippocampus.
Topics: Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Animals; Aspartate Aminotransferase, Cy | 2017 |
(1)H-MRS asymmetry changes in the anterior and posterior cingulate gyrus in patients with mild cognitive impairment and mild Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Cognitive Dysfunction; Creatine; Dominance, Cerebra | 2016 |
Whole-brain patterns of (1)H-magnetic resonance spectroscopy imaging in Alzheimer's disease and dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Case-Control Studies; Choline; Cre | 2016 |
Isomerization of the Asp7 residue results in zinc-induced oligomerization of Alzheimer's disease amyloid beta(1-16) peptide.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Aspartic Acid; Humans; Kinetics; Pept | 2008 |
Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Case-Control Studie | 2008 |
Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease.
Topics: Aged; alpha-Macroglobulins; Alzheimer Disease; Aspartic Acid; Biomarkers; Complement Factor H; Disea | 2008 |
Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Cognition Disorders; Creatine; Dominance, | 2009 |
Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition; Cognition Disorders; Creatine; De | 2009 |
A multicenter (1)H-MRS study of the medial temporal lobe in AD and MCI.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Biomarkers; Cognition Disorders; Female; Humans; Magnetic Re | 2009 |
Heteroplasmy of mitochondrial D310 mononucleotide repeat region in the blood of patients with Alzheimer's disease.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Blood Cells; Cognition Disorders; | 2009 |
Toward proteome-scale identification and quantification of isoaspartyl residues in biological samples.
Topics: Alzheimer Disease; Aspartic Acid; Cell Line; Fourier Analysis; Humans; Isoaspartic Acid; Isomerism; | 2009 |
Mechanism of cytotoxicity mediated by the C31 fragment of the amyloid precursor protein.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Se | 2009 |
Metabolic changes in rat brain following intracerebroventricular injections of streptozotocin: a model of sporadic Alzheimer's disease.
Topics: Alzheimer Disease; Amino Acids; Animals; Aspartic Acid; Brain; Brain Chemistry; Disease Models, Anim | 2010 |
Deprotonation of the Asp1-Ala2 peptide bond induces modification of the dynamic copper(II) environment in the amyloid-beta peptide near physiological pH.
Topics: Alanine; Alzheimer Disease; Amyloid beta-Peptides; Aspartic Acid; Binding Sites; Copper; Dipeptides; | 2009 |
Absolute quantification in proton magnetic resonance spectroscopy is useful to differentiate amnesic mild cognitive impairment from Alzheimer's disease and healthy aging.
Topics: Aged; Aging; Alzheimer Disease; Amnesia; Analysis of Variance; Aspartic Acid; Biomarkers; Brain Chem | 2010 |
Reduction of hippocampal N-acetyl aspartate level in aged APP(Swe)/PS1(dE9) transgenic mice is associated with degeneration of CA3 pyramidal neurons.
Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Benzothiazoles; CA | 2010 |
Structural design, solid-phase synthesis and activity of membrane-anchored β-secretase inhibitors on Aβ generation from wild-type and Swedish-mutant APP.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amylo | 2010 |
Hippocampal proton MR spectroscopy in early Alzheimer's disease and mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Case-Control Studies; Choline; Cognitive | 2011 |
Truncated tau and Aβ cooperatively impair mitochondria in primary neurons.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Aspartic Acid; Cell Line, Transformed; Down-Regul | 2012 |
Down syndrome with and without dementia: an in vivo proton Magnetic Resonance Spectroscopy study with implications for Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Case-Control Studies; Dementia; Down Syndro | 2011 |
Using proton magnetic resonance spectroscopy to identify mild cognitive impairment.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Case-Control Studies; Choline; Cognitive Dysfunction; | 2012 |
Alzheimer's disease and mild cognitive impairment are associated with elevated levels of isoaspartyl residues in blood plasma proteins.
Topics: Alzheimer Disease; Aspartic Acid; Blood Proteins; Cognitive Dysfunction; Female; Humans; Male; Mass | 2011 |
Association of N-acetylaspartate and cerebrospinal fluid Aβ42 in dementia.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Aspartic Acid; Biomarkers; Cognitive Dysfunction; De | 2011 |
Ubiquitin is associated with early truncation of tau protein at aspartic acid(421) during the maturation of neurofibrillary tangles in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Amino Acid Sequence; Apoptosis; Aspartic Acid; Humans; Mutation; Neurofibri | 2012 |
Brain glutamate levels are decreased in Alzheimer's disease: a magnetic resonance spectroscopy study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Choline; Cognitive Dysfunction; Creatine; | 2011 |
Magnetic resonance spectroscopic methods for the assessment of metabolic functions in the diseased brain.
Topics: Alzheimer Disease; Aspartic Acid; Brain; Humans; Isotopes; Magnetic Resonance Spectroscopy; Parkinso | 2012 |
N-acetylaspartate, choline, myoinositol, glutamine and glutamate (glx) concentration changes in proton MR spectroscopy (1H MRS) in patients with mild cognitive impairment (MCI).
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Cognitive Dysfunction; Disease Progression; Female; | 2011 |
Effects of Alzheimer's disease transgenes on neurochemical expression in the mouse brain determined by ¹H MRS in vitro.
Topics: Alzheimer Disease; Analysis of Variance; Animals; Aspartic Acid; Biomarkers; Brain; Choline; Glycery | 2012 |
Contribution of 1H spectroscopy to a brief cognitive-functional test battery for the diagnosis of mild Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Cognitive Dys | 2011 |
Longitudinal magnetic resonance spectroscopy as marker of cognitive deterioration in mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Cognitive Dysfunction; Creatine; F | 2011 |
Regulation of mitochondrial transport and inter-microtubule spacing by tau phosphorylation at the sites hyperphosphorylated in Alzheimer's disease.
Topics: Alanine; Alzheimer Disease; Animals; Aspartic Acid; Biological Transport; Cells, Cultured; Chloroceb | 2012 |
Proton and phosphorus magnetic resonance spectroscopy of a mouse model of Alzheimer's disease.
Topics: Adenosine Triphosphate; Algorithms; Alzheimer Disease; Animals; Aspartic Acid; Brain; Brain Chemistr | 2012 |
Functional investigation of bilateral posterior cingulate gyri using multivoxel MR spectroscopy.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Cognitive Dys | 2012 |
Amyloid-beta (Aβ) D7H mutation increases oligomeric Aβ42 and alters properties of Aβ-zinc/copper assemblies.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Aspar | 2012 |
Metabolite investigation in both anterior and posterior cingulate gyri in Alzheimer's disease spectrum using 3-tesla MR spectroscopy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Cognition Disorders; Creatine; Disease Pr | 2012 |
Age-related changes in brain metabolites and cognitive function in APP/PS1 transgenic mice.
Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Biomarkers; Cholin | 2012 |
Altered neurochemical profile in the McGill-R-Thy1-APP rat model of Alzheimer's disease: a longitudinal in vivo 1 H MRS study.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Choline; Cre | 2012 |
Parkin prevents cortical atrophy and Aβ-induced alterations of brain metabolism: ¹³C NMR and magnetic resonance imaging studies in AD models.
Topics: Adaptor Proteins, Signal Transducing; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein | 2012 |
MICEST: a potential tool for non-invasive detection of molecular changes in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Biomarkers; Brain Mapping | 2013 |
1H-MRS assessment of the therapeutic effect of bilateral intraventricular BDNF infusion into APP/PS1 double transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Br | 2013 |
Longitudinal monitoring of sex-related in vivo metabolic changes in the brain of Alzheimer's disease transgenic mouse using magnetic resonance spectroscopy.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of V | 2013 |
A quantitative analysis of spontaneous isoaspartate formation from N-terminal asparaginyl and aspartyl residues.
Topics: Alzheimer Disease; Amino Acid Motifs; Amino Acid Sequence; Amyloid beta-Peptides; Asparagine; Aspart | 2013 |
Presenilin-1 affects trafficking and processing of betaAPP and is targeted in a complex with nicastrin to the plasma membrane.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2002 |
Proton magnetic resonance spectroscopy reveals similar white matter biochemical changes in patients with chronic hypertension and early Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Choline; Chronic Disease; Creatine | 2002 |
In-vivo proton MR-spectroscopy of the human brain: assessment of N-acetylaspartate (NAA) reduction as a marker for neurodegeneration.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Biomarkers; Brain; Female; Humans; Magnetic Resonance Spectr | 2002 |
Isoaspartate formation at position 23 of amyloid beta peptide enhanced fibril formation and deposited onto senile plaques and vascular amyloids in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Aspartic Aci | 2002 |
Quantification of neurons in Alzheimer and control brains with ex vivo high resolution magic angle spinning proton magnetic resonance spectroscopy and stereology.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Case-Control Studie | 2002 |
Axonal injury within language network in primary progressive aphasia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aphasia, Primary Progressive; Aspartic Acid; Axons; Crea | 2003 |
Cognitive impairment: assessment with brain magnetic resonance imaging and proton magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Chemistry; Choline; Cognition Disorders; Creati | 2003 |
Brain damage results in down-regulation of N-acetylaspartate as a neuronal osmolyte.
Topics: Alzheimer Disease; Animals; Aspartic Acid; Biomarkers; Brain; Brain Diseases; Cell Survival; Cells, | 2003 |
Higher field strength for proton MR spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Cognition Disorders; Creatinine; Humans; Inositol; Ma | 2003 |
Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition Disorders; Crea | 2003 |
The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: a proton magnetic resonance spectroscopy study.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Cognition Disorders; Creatinine; Dementia, Vascular | 2003 |
Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Antibodies, Monoclonal; Apoptosis; Aspar | 2003 |
Synaptic vesicle transport and synaptic membrane transporter sites in excitatory amino acid nerve terminals in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Binding Sites; Biological Transport; Cerebral Cortex; Down-R | 2003 |
Posterior cingulate metabolic changes in frontotemporal lobar degeneration detected by magnetic resonance spectroscopy.
Topics: Adult; Aged; Alzheimer Disease; Aspartic Acid; Case-Control Studies; Choline; Creatine; Dementia; Di | 2004 |
1H MR spectroscopy in common dementias.
Topics: Acetylcholine; Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Brain Chemistry; Ch | 2004 |
In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Brain Mapping; Case | 2004 |
Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Biomarkers; | 2005 |
Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease.
Topics: Alzheimer Disease; Antigens; Aspartic Acid; Blotting, Western; Brain; Fluorescent Antibody Technique | 2005 |
1H MR spectroscopy using TE averaged PRESS: a more sensitive technique to detect neurodegeneration associated with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Algorithms; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Brain C | 2005 |
Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition Disorders; Cohort Studies; Creatin | 2005 |
A whole brain MR spectroscopy study from patients with Alzheimer's disease and mild cognitive impairment.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Atrophy; Brain; Brain Chemistry; Cognition Disorders; Female | 2005 |
Evidence of biochemical and biomagnetic interactions in Alzheimer's disease: an MEG and MR spectroscopy study.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Biomarkers; Brain Chemistry; Creatine; Female; Humans; Inosi | 2005 |
A comparative study of the different N-acetylaspartate measures of the medial temporal lobe in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Creatine; Female; Humans; Magnetic Resonance Spectr | 2005 |
Amino acids and transaminases activity in ventricular CSF and in brain of normal and Alzheimer patients.
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Alzheimer Disease; Amino Acids; Aspartate Aminotransf | 2005 |
Alzheimer's disease and proton magnetic resonance spectroscopy of limbic regions: a suggestion of a clinical-spectroscopic staging.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Animals; Aspartic Acid; Case-Contr | 2005 |
SET protein (TAF1beta, I2PP2A) is involved in neuronal apoptosis induced by an amyloid precursor protein cytoplasmic subdomain.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Apoptosis; Aspartic Acid; Biological Ass | 2005 |
C-terminal truncation modulates both nucleation and extension phases of tau fibrillization.
Topics: Alzheimer Disease; Aspartic Acid; Caspases; Glutamic Acid; Humans; Membrane Proteins; Multiprotein C | 2006 |
[Proton spectroscopy in Alzheimer's disease and cognitive impairment not dementia: a community study].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Case-Control Studies; Choline; Cognition | 2005 |
Magnetic resonance spectroscopic study of Alzheimer's disease and frontotemporal dementia/Pick complex.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain Mapping; Cerebral Cortex; Creatine; Dementia; Down-Reg | 2006 |
Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Amino Acid Sequence; Antibodies; Apoptosis; Aspar | 2006 |
Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Astrocytes; Behavior, Ani | 2006 |
Regulation of NAA-synthesis in the human brain in vivo: Canavan's disease, Alzheimer's disease and schizophrenia.
Topics: Alzheimer Disease; Aspartic Acid; Brain; Canavan Disease; Child; Glutamic Acid; Humans; Magnetic Res | 2006 |
Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Choline; Cognition | 2007 |
Treatment monitoring and response prediction with proton MR spectroscopy in AD.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Creatine; Female; Humans; Magnetic Resonance Spectroscopy; M | 2006 |
Structural and thermodynamical properties of CuII amyloid-beta16/28 complexes associated with Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Aspartic Acid; Binding Sites; Copper; Humans; Peptide Frag | 2006 |
Posterior cingulate neurometabolite profiles and clinical phenotype in frontotemporal dementia.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Atrophy; Dementia; Diagnosis, Differential; Female; Frontal | 2006 |
Evaluation of neuroprotective effects of long-term low dose hormone replacement therapy on postmenopausal women brain hippocampus using magnetic resonance scanner.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoprotein E3; Aspartic Acid; Creatine; Dose-Respons | 2006 |
Elevated brain scyllo-inositol concentrations in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Biopsy; Brain; Cognition Disorders; Creatine; Female; Humans | 2007 |
Role of aspartate-1 in Cu(II) binding to the amyloid-beta peptide of Alzheimer's disease.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Aspartic Acid; Copper; Electron Spin | 2007 |
A decrease in N-acetylaspartate and an increase in myoinositol in the anterior cingulate gyrus are associated with behavioral and psychological symptoms in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Cognition Disorders; Cre | 2007 |
Effects of long-term, low-dose sex hormone replacement therapy on hippocampus and cognition of postmenopausal women of different apoE genotypes.
Topics: Aged; Alzheimer Disease; Apolipoproteins E; Aspartic Acid; Cognition; Creatinine; Cross-Sectional St | 2007 |
Cortical brain metabolism as measured by proton spectroscopy is related to memory performance in patients with amnestic mild cognitive impairment and Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Amnesia; Aspartic Acid; Cerebral Cortex; Cognition Disorders; Creatine; Fem | 2007 |
Reproducibility of magnetic resonance spectroscopy in correlation with signal-to-noise ratio.
Topics: Aged; Alzheimer Disease; Artifacts; Aspartic Acid; Choline; Creatine; Female; Gyrus Cinguli; Humans; | 2007 |
Signal transduction in Alzheimer disease: p21-activated kinase signaling requires C-terminal cleavage of APP at Asp664.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; | 2008 |
Potent memapsin 2 (beta-secretase) inhibitors: design, synthesis, protein-ligand X-ray structure, and in vivo evaluation.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid; Aspartic Acid Endop | 2008 |
Association between Alzheimer's disease and the NOS3 gene Glu298Asp polymorphism in Chinese.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoprotein E4; Asian People; Aspartic Acid; Female; | 2008 |
C-terminal cleavage of the amyloid-beta protein precursor at Asp664: a switch associated with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alcohol Oxidoreductases; Alzheimer Disease; Amyloid beta-Protein Precursor; | 2008 |
Accumulation of aspartic acid421- and glutamic acid391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Amino Acid Sequence; Apolipoprotein E4; Aspartic Acid; Brain; Disease Progr | 2008 |
Long-term prevention of Alzheimer's disease-like behavioral deficits in PDAPP mice carrying a mutation in Asp664.
Topics: Age Factors; Alanine; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Anal | 2008 |
Amino acid release from biopsy samples of temporal neocortex from patients with Alzheimer's disease.
Topics: Acetylcholine; Alzheimer Disease; Amino Acids; Aspartic Acid; Dementia; gamma-Aminobutyric Acid; Glu | 1983 |
Intralaminar neurochemical distributions in human midtemporal cortex: comparison between Alzheimer's disease and the normal.
Topics: Acetylcholinesterase; Alzheimer Disease; Aspartic Acid; Butyrylcholinesterase; Cerebral Cortex; Chol | 1984 |
Hippocampal free amino acids in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Amino Acids; Arginine; Aspartic Acid; Dementia; gamma-Aminobutyric Acid; Gl | 1980 |
beta-Amyloid peptide fragment 25-35 potentiates the calcium-dependent release of excitatory amino acids from depolarized hippocampal slices.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Aspartic Acid; Calcium; Excitatory Amino Acids; g | 1995 |
H-1 MR spectroscopic imaging of white matter signal hyperintensities: Alzheimer disease and ischemic vascular dementia.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Diseases; Brain Ischemia; Case-Control Studies; | 1995 |
[1H-MR spectroscopic imaging in patients with clinically diagnosed Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Choline; Creatine; Hippocampus; Humans; Lactates; Lac | 1995 |
Role of increased cerebral myo-inositol in the dementia of Down syndrome.
Topics: Adolescent; Adult; Alzheimer Disease; Aspartic Acid; Brain; Child; Child, Preschool; Choline; Creati | 1995 |
Brain N-acetyl-L-aspartic acid in Alzheimer's disease: a proton magnetic resonance spectroscopy study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Cerebral Cortex; Female; Hippocampus; Hum | 1994 |
N-acetylaspartate and N-acetylaspartylglutamate levels in Alzheimer's disease post-mortem brain tissue.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amygdala; Aspartic Acid; Brain Chemistry; Cerebellar Cor | 1994 |
Variant forms of neuronal glutamate transporter sites in Alzheimer's disease cerebral cortex.
Topics: Aged; Alzheimer Disease; Amino Acid Transport System X-AG; Aspartic Acid; ATP-Binding Cassette Trans | 1995 |
An in vitro 1H nuclear magnetic resonance study of the temporoparietal cortex of Alzheimer brains.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Creatinine; Female; gamma-Aminobutyric Ac | 1995 |
Racemization: its biological significance on neuropathogenesis of Alzheimer's disease.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Aspartic Acid; Biopolymers; Brain; Hu | 1994 |
Reduced N-acetylaspartate content in the frontal part of the brain in patients with probable Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Choline; Creatine; Female; Frontal Lobe; | 1995 |
Detection of D-aspartate in tau proteins associated with Alzheimer paired helical filaments.
Topics: Alzheimer Disease; Amino Acids; Aspartic Acid; Brain Chemistry; Electrophoresis, Polyacrylamide Gel; | 1995 |
Comments on use of H-1 MR spectroscopy for diagnosis of probable Alzheimer disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Creatine; Humans; Inositol; Magnetic Resonance Spectr | 1995 |
Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging.
Topics: Aged; Aging; Alzheimer Disease; Aspartic Acid; Axons; Brain; Cerebral Cortex; Cerebral Ventricles; C | 1994 |
Plasma concentrations of glutamate and its metabolites in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aminobutyrates; Aspartic Acid; Discriminant Analysis; Fe | 1993 |
Racemization of Asp23 residue affects the aggregation properties of Alzheimer amyloid beta protein analogues.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Aspartic Acid; Humans; Molecular Sequ | 1994 |
Relationship between beta-amyloid precursor protein, pyramidal neurones and astrocytes in human neocortex.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Antibodies, Monoclonal; Aspartic Acid; Biological | 1993 |
Proton magnetic resonance spectroscopy with dementia.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Creatine; Dementia; Female; Humans | 1993 |
In vivo proton magnetic resonance spectroscopy study on premature aging in adult Down's syndrome.
Topics: Adult; Alzheimer Disease; Aspartic Acid; Brain; Cellular Senescence; Choline; Creatinine; Down Syndr | 1993 |
Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Aspartic Acid; Brain; Brain Chemistry | 1993 |
Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Cerebral Cortex; Choline; Creatine; Female; Humans; Inositol | 1993 |
Mineralization of the globus pallidus following excitotoxic lesions of the basal forebrain.
Topics: Alzheimer Disease; Animals; Aspartic Acid; Calcinosis; Cholinergic Fibers; Down Syndrome; Globus Pal | 1995 |
1H-MRS, MRI-based hippocampal volumetry, and 99mTc-HMPAO-SPECT in normal aging, age-associated memory impairment, and probable Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Case-Control Stud | 1996 |
Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Brain; Brain Ischem | 1996 |
CSF excitatory amino acids and severity of illness in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Glutamine; Humans; Middle Aged; Neuropsychological Tests; Se | 1996 |
Evaluation of automated MR spectroscopy: application in Alzheimer disease.
Topics: Adult; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Choline; Creatine; Female; Humans; Inosito | 1995 |
Proton magnetic resonance spectroscopy of vascular- and Alzheimer-type dementia.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Choline; Creatine; Dementia, Vascular; Diagnosis, Dif | 1996 |
A novel mutation of presenilin 1 in familial Alzheimer's disease in Israel detected by denaturing gradient gel electrophoresis.
Topics: Alzheimer Disease; Aspartic Acid; Electrophoresis, Polyacrylamide Gel; Exons; Female; Glutamic Acid; | 1996 |
Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Animals; Aspartic Acid; Binding Sites | 1997 |
Regional metabolic alterations in Alzheimer's disease: an in vitro 1H NMR study of the hippocampus and cerebellum.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Cadaver; Cerebellum; Female; Hippo | 1997 |
Proton magnetic resonance spectroscopy in dementia of Alzheimer type.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Choline; Creatine; Female; Humans; | 1997 |
Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Dementia; Discriminant Analysis; Female; | 1997 |
[1H-MRSI of Alzheimer's disease].
Topics: Adult; Aged; Alzheimer Disease; Aspartic Acid; Biomarkers; Brain; Female; Humans; Magnetic Resonance | 1997 |
N-acetylaspartylglutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases.
Topics: Alzheimer Disease; Amino Acids; Antigens, Surface; Aspartic Acid; Brain; Case-Control Studies; Cell | 1997 |
Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Atrophy; Female; Hippocampus; Humans; Mag | 1997 |
Alzheimer disease: quantitative H-1 MR spectroscopic imaging of frontoparietal brain.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Artifacts; Aspartic Acid; Brain Chemistry; Choline; Crea | 1998 |
[Clinical uses of proton magnetic resonance spectroscopy of the brain].
Topics: AIDS Dementia Complex; Alzheimer Disease; Animals; Aspartic Acid; Brain; Brain Diseases; Brain Disea | 1998 |
Regional decreases of free D-aspartate levels in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Brain Chemistry; Chromatography, H | 1998 |
Metabolic brain mapping in Alzheimer's disease using proton magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Mapping; Choline; Creatine; Female; Humans; Ino | 1998 |
Prediction of cognitive decline in early Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Cognition; Disease Progression; Humans; Mag | 1998 |
Deamidation and isoaspartate formation in smeared tau in paired helical filaments. Unusual properties of the microtubule-binding domain of tau.
Topics: Alzheimer Disease; Amides; Amino Acid Sequence; Aspartic Acid; Blotting, Western; Brain; Humans; Imm | 1999 |
Immunohistochemical localization of amyloid beta-protein with amino-terminal aspartate in the cerebral cortex of patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Aspartic Acid; Cerebral Cortex; D | 1999 |
Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 1999 |
Synthesis, aggregation, and neurotoxicity of the Alzheimer's Abeta1-42 amyloid peptide and its isoaspartyl isomers.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Aspartic Acid; Cell Survival; Chromatography, Hig | 1999 |
Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation.
Topics: Acute Disease; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Pre | 1999 |
The presence of isoaspartic acid in beta-amyloid plaques indicates plaque age.
Topics: Adult; Aged; Aged, 80 and over; Aging; Alzheimer Disease; Antibodies; Aspartic Acid; Autopsy; Biomar | 1999 |
Chemical modifications of deposited amyloid-beta peptides.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Aspartic Acid; Humans; Molecular Sequ | 1999 |
Zebrafish (Danio rerio) presenilin promotes aberrant amyloid beta-peptide production and requires a critical aspartate residue for its function in amyloidogenesis.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Animals; Aspartic Acid; Cell Line; Co | 1999 |
Protein aging hypothesis of Alzheimer disease.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Animals; Aspartic Acid; Biopolymers; | 2000 |
Modeling of substrate specificity of the Alzheimer's disease amyloid precursor protein beta-secretase.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Se | 2000 |
Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Disease Progression; Female; Human | 2000 |
Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain Mapping; Choline; Cognition Disorde | 2000 |
beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Aspartic Acid; Astrocytes; Basal Nucleus of Meyne | 2000 |
Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Female; Humans; Magnetic Resonance Imaging; Magnetic Resonan | 2000 |
No evidence for an association between the Glu298Asp polymorphism of the NOS3 gene and Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Child; Female; Gene Frequency; Genotype; Glutamic Acid; Huma | 2000 |
Mutation of conserved aspartates affect maturation of presenilin 1 and presenilin 2 complexes.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Aspartic Ac | 2000 |
The Glu298Asp polymorphism in the NOS3 gene is not associated with sporadic Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Glutamic Acid; Humans; Middle Aged; Nitri | 2001 |
Relation between 1H MR spectroscopic imaging and regional cerebral glucose metabolism in Alzheimer's disease.
Topics: Adult; Aged; Alzheimer Disease; Aspartic Acid; Brain; Choline; Female; Glucose; Humans; Magnetic Res | 2001 |
Drastic neuronal loss in vivo by beta-amyloid racemized at Ser(26) residue: conversion of non-toxic [D-Ser(26)]beta-amyloid 1-40 to toxic and proteinase-resistant fragments.
Topics: Alzheimer Disease; Amino Acid Isomerases; Amino Acid Sequence; Aminopeptidases; Amyloid beta-Peptide | 2001 |
Effects of ENA713 and CHF2819, two anti-Alzheimer's disease drugs, on rat amino acid levels.
Topics: Alzheimer Disease; Animals; Arginine; Aspartic Acid; Carbamates; Cholinesterase Inhibitors; Citrulli | 2001 |
(1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Choline; Cognitio | 2001 |
Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Brain; Choline; Cre | 2001 |
Disturbed activation of endoplasmic reticulum stress transducers by familial Alzheimer's disease-linked presenilin-1 mutations.
Topics: Alzheimer Disease; Animals; Aspartic Acid; Blotting, Western; Down-Regulation; Endoplasmic Reticulum | 2001 |
Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Cognition Disorders; Creatine; Cross-Sectional Studies; Fema | 2001 |
Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Amyloidosis; Asparagine; Aspartic Aci | 2001 |
A novel presenilin 2 gene mutation (D439A) in a patient with early-onset Alzheimer's disease.
Topics: Alanine; Alzheimer Disease; Amino Acid Substitution; Aspartic Acid; Genetic Carrier Screening; Human | 2001 |
MRI white matter hyperintensities, (1)H-MR spectroscopy and cognitive function in geriatric depression: a comparison of early- and late-onset cases.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Choline; Creatine; Depressive Disorder, Major; Energy | 2001 |
Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Atrophy; Female; Hu | 2002 |
Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Creatine; Female; Glutamic Acid; Glutamine; Humans; M | 2002 |
Regional N-acetylaspartate reduction in the hippocampus detected with fast proton magnetic resonance spectroscopic imaging in patients with Alzheimer disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Creatine; Female; Hippocampus; Humans; Magnetic Res | 2002 |
N-acetyl-L-aspartate and other amino acid metabolites in Alzheimer's disease brain: a preliminary proton nuclear magnetic resonance study.
Topics: Aged; Alzheimer Disease; Amino Acids; Aspartic Acid; Brain; Cadaver; Female; Glutamates; Glutamic Ac | 1992 |
Quantification of D-aspartate in normal and Alzheimer brains.
Topics: Alzheimer Disease; Amino Acid Oxidoreductases; Aspartate Aminotransferases; Aspartic Acid; Brain Che | 1992 |
Altered aspartate in Alzheimer neurofibrillary tangles.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Female; Humans; Male; Methylation; | 1992 |
Racemized D-aspartate in Alzheimer neurofibrillary tangles.
Topics: Alzheimer Disease; Aspartic Acid; Benzothiazoles; Chromatography, Gas; Fluorescent Dyes; Humans; Ner | 1992 |
Free D-aspartate and D-alanine in normal and Alzheimer brain.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Humans; | 1991 |
Distribution of neurofibrillary tangle formation and [3H]-D-aspartate receptor binding in the thalamus in the normal elderly brain, in Alzheimer's disease and in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Autoradiography; Female; Humans; Male; Ne | 1990 |
[3H]N-[1-(2-thienyl)cyclohexyl]-3,4-piperidine ([3H]TCP) binding in human frontal cortex: decreases in Alzheimer-type dementia.
Topics: Alzheimer Disease; Aspartic Acid; Binding Sites; Frontal Lobe; Glutamates; Glutamic Acid; Humans; Me | 1990 |
Differential alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer type.
Topics: Aged; Aged, 80 and over; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease | 1990 |
Sodium dependent D-[3H]aspartate binding in cerebral cortex in patients with Alzheimer's and Parkinson's diseases.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Cerebral Cortex; Choline O-Acetyltransfer | 1987 |
Regional changes in [3H]D-aspartate and [3H]TCP binding sites in Alzheimer's disease brains.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Female; Humans; Male; Phencyclidine; Rece | 1988 |
Putative amino acid transmitters in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia.
Topics: Adult; Aged; Alzheimer Disease; Amino Acids; Aspartic Acid; Dementia; Epilepsy; Female; Glutamates; | 1985 |
Controlled induction of paired helical filaments of the Alzheimer type in cultured human neurons, by glutamate and aspartate.
Topics: Alzheimer Disease; Aspartic Acid; Culture Techniques; Cytoskeleton; Fetus; Glutamates; Glutamic Acid | 1985 |
Regional distribution of amino acid transmitters in postmortem brains of presenile and senile dementia of Alzheimer type.
Topics: Aged; Aging; Alzheimer Disease; Aspartic Acid; Female; gamma-Aminobutyric Acid; Glutamates; Glutamic | 1986 |
Plasticity in hippocampal excitatory amino acid receptors in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Autoradiography; Female; Glutamates; Glutamic Acid; Hippocam | 1986 |
A postmortem study of amino acid neurotransmitters in Alzheimer's disease.
Topics: Aged; Aging; Alanine; Alzheimer Disease; Amino Acids; Aspartic Acid; Brain; gamma-Aminobutyric Acid; | 1986 |
Dementia of the Alzheimer's type: changes in hippocampal L-[3H]glutamate binding.
Topics: Alzheimer Disease; Aspartic Acid; Autoradiography; Flunitrazepam; Glutamates; Glutamic Acid; Hippoca | 1987 |
Glutamate deficits in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Glutamates; Glutamic Acid; Humans; | 1987 |
Region-specific loss of glutamate innervation in Alzheimer's disease.
Topics: Alzheimer Disease; Aspartic Acid; Brain; Cerebral Cortex; Glutamates; Glutamic Acid; Hippocampus; Hu | 1987 |
The dementia of Alzheimer's disease: an update.
Topics: Afferent Pathways; Alzheimer Disease; Amygdala; Animals; Aspartic Acid; Glutamates; Glutamic Acid; M | 1987 |
Glutamatergic denervation in Alzheimer's disease--a cautionary note.
Topics: Alzheimer Disease; Aspartic Acid; Brain; Glutamates; Glutamic Acid; Humans; Nerve Degeneration | 1987 |
Presynaptic and postsynaptic glutamatergic function in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Female; Glutamates; Glutamic Acid; Humans | 1988 |
Topographical distribution of neurochemical changes in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amino Acids, Dicarboxylic; Asparagine; Aspartic Acid; Ce | 1988 |
Regional distribution of pre- and postsynaptic glutamatergic function in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Caudate Nucleus; Cerebral Cortex; | 1988 |
Anatomical organization of excitatory amino acid receptors and their properties.
Topics: Alzheimer Disease; Animals; Aspartic Acid; Autoradiography; Brain; Brain Mapping; Calcium; Glutamate | 1986 |
Neuritic plaque amyloid in Alzheimer's disease is highly racemized.
Topics: Aged; Alzheimer Disease; Amino Acids; Amyloid; Amyloid beta-Peptides; Aspartic Acid; Brain Chemistry | 1988 |
Glutamate/aspartate-releasing neurons in Alzheimer's disease.
Topics: Alzheimer Disease; Aspartic Acid; Glutamates; Humans; In Vitro Techniques; Neurons; Temporal Lobe | 1986 |
D-aspartate in human brain.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Alzheimer Disease; Aspartic Acid; Brain; Brain Di | 1987 |